<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Medication-related osteonecrosis of the jaw in patients with cancer</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Medication-related osteonecrosis of the jaw in patients with cancer</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Medication-related osteonecrosis of the jaw in patients with cancer</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">James R Berenson, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Alison T Stopeck, MD</a></dd><dt><span> </span>Section Editors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Reed E Drews, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">S Vincent Rajkumar, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Melinda Yushak, MD, MPH</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Jan 26, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H664776058"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Medication-related osteonecrosis of the jaw (MRONJ  (<a class="graphic graphic_diagnosticimage graphicRef55727" href="/z/d/graphic/55727.html" rel="external">image 1</a>)), which was first described in 2002 [<a href="#rid1">1</a>], is a relatively uncommon but potentially serious side effect of treatment with osteoclast inhibitors, such as intravenous high-potency bisphosphonates and <a class="drug drug_general" data-topicid="15575" href="/z/d/drug information/15575.html" rel="external">denosumab</a>, which decrease the risk of skeletal-related events in patients with cancer and metastatic bone disease. The increased dose intensity of osteoclast inhibitors typically prescribed for cancer indications places cancer patients at a substantially higher risk for MRONJ than patients who receive them for other conditions, such as osteoporosis and Paget disease [<a href="#rid2">2-5</a>].</p><p>MRONJ has also been described as a complication of cancer therapies that target angiogenesis; however, this association is more controversial, with little confirmatory prospective trial data available in the setting of monotherapy with an antiangiogenic agent alone. Use of antiangiogenic agents as a risk factor for MRONJ among patients receiving osteoclast inhibitors for cancer is more clearly established. (See  <a class="medical medical_review" href="/z/d/html/86366.html" rel="external">"Non-cardiovascular toxicities of molecularly targeted antiangiogenic agents", section on 'Osteonecrosis of the jaw'</a>.)</p><p>This topic review will describe the incidence, risk factors, staging, clinical course, prevention strategies, and management of MRONJ in patients with cancer who are receiving osteoclast inhibitors and antiangiogenic agents. The incidence, risk factors, and management strategies for MRONJ in patients receiving osteoclast inhibitors for osteoporosis, and other side effects associated with bisphosphonates and <a class="drug drug_general" data-topicid="15575" href="/z/d/drug information/15575.html" rel="external">denosumab</a> in patients with cancer are addressed elsewhere. (See  <a class="medical medical_review" href="/z/d/html/2067.html" rel="external">"Denosumab for osteoporosis", section on 'Oversuppression of bone remodeling'</a> and  <a class="medical medical_review" href="/z/d/html/2806.html" rel="external">"Risks of therapy with bone antiresorptive agents in patients with advanced malignancy"</a>.)</p><p class="headingAnchor" id="H664776064"><span class="h1">NOMENCLATURE AND DEFINITION</span><span class="headingEndMark"> — </span>Osteonecrosis associated with bisphosphonate treatment has been referred to by several acronyms, including BRMRONJ (bisphosphonate-related MRONJ), BRON (bisphosphonate-related osteonecrosis), BON (bisphosphonate osteonecrosis), BAMRONJ (bisphosphonate-associated MRONJ), and simply MRONJ. The recognition of jaw necrosis as a complication of other drugs, including the receptor activator of nuclear factor kappa B ligand (RANKL) inhibitor <a class="drug drug_general" data-topicid="15575" href="/z/d/drug information/15575.html" rel="external">denosumab</a> and antiangiogenic agents, prompted a special committee of the American Association of Oral and Maxillofacial Surgeons (AAOMS) to recommend the term "medication-related osteonecrosis of the jaw" as preferred [<a href="#rid6">6</a>], and this terminology is also endorsed in joint guidelines from the Multinational Association of Supportive Care in Cancer (MASCC)/International Society of Oral Oncology (ISOO)/American Society of Clinical Oncology (ASCO) [<a href="#rid7">7</a>].</p><p class="headingAnchor" id="H664779733"><span class="h2">Definition</span><span class="headingEndMark"> — </span>Two working definitions of MRONJ have been proposed:</p><p class="bulletIndent1"><span class="glyph">●</span>A task force convened by the American Society for Bone and Mineral Research (ASBMR) defines MRONJ as the presence of exposed bone in the maxillofacial region that does not heal within eight weeks after identification by a health care professional [<a href="#rid2">2</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>An updated 2022 position paper on MRONJ is available from the AAOMS, which provides an updated definition of the condition, comparative risk estimates of developing MRONJ in patients with cancer and a history of exposure to osteoclast inhibitors and/or antiangiogenic agents, recommendations for prevention measures, and management strategies for patients with established MRONJ [<a href="#rid8">8</a>].</p><p></p><p class="bulletIndent1">Patients may be considered to have MRONJ if all of the following characteristics are present:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Current or previous treatment with antiresorptive therapy alone or in combination with immune modulators or antiangiogenic agents.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Exposed bone or bone that can be probed through an intraoral or extraoral fistula(e) in the maxillofacial region that has persisted for more than eight weeks.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>No history of radiation therapy to metastatic disease in the jaws.</p><p></p><p>We prefer the AAOMS definition, which has also been adopted by an international task force on osteonecrosis of the jaw [<a href="#rid9">9</a>] and in joint guidelines on MRONJ from the MASCC/ISOO/ASCO [<a href="#rid7">7</a>].</p><p class="headingAnchor" id="H664776070"><span class="h1">PATHOPHYSIOLOGY</span><span class="headingEndMark"> — </span>Although the first cases of MRONJ were reported first in 2002, the underlying pathophysiology is still not fully elucidated. The leading proposed hypotheses to explain the unique localization of MRONJ to the jaws include oversuppression of bone turnover or remodeling, inhibition of blood supply, constant microtrauma, and infection/inflammation. None of these hypotheses seems to explain all cases [<a href="#rid10">10</a>].</p><p class="bulletIndent1"><span class="glyph">●</span>The shared complication of MRONJ in cancer patients treated with high doses of <a class="drug drug_general" data-topicid="15575" href="/z/d/drug information/15575.html" rel="external">denosumab</a> or potent bisphosphonates strongly suggests that profound and prolonged inhibition of bone resorption with oversuppression of bone remodeling (ie, low bone turnover), and infection are the main mechanisms [<a href="#rid11">11</a>]. Animal data support the view that a higher rate of bone remodeling or more severe oversuppression of the bone turnover rate with bisphosphonates in the jawbones may explain the differential predisposition at this site compared with other bones in the axial or appendicular skeleton [<a href="#rid12">12,13</a>]. However, this is probably not the sole contributor since MRONJ can be, albeit rarely, observed in the absence of osteoclast inhibitor therapy. Other animal studies suggest defects in alveolar bone such as dental extractions to be potent initiators for MRONJ, with mucosal or soft tissue damage less likely to induce necrosis [<a href="#rid14">14</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Some have postulated that MRONJ is a form of avascular necrosis, possibly caused by inhibition of angiogenesis. In vitro experiments consistently demonstrate that <a class="drug drug_general" data-topicid="9902" href="/z/d/drug information/9902.html" rel="external">zoledronic acid</a> inhibits angiogenesis, and cancer patients treated with this agent have decreased circulating vascular endothelial growth factor (VEGF) levels [<a href="#rid15">15,16</a>]. Moreover, there is a growing body of evidence linking MRONJ to antiangiogenic drugs, including <a class="drug drug_general" data-topicid="8683" href="/z/d/drug information/8683.html" rel="external">bevacizumab</a> and orally active tyrosine kinase inhibitors. However, inhibition of angiogenesis has not been reported with <a class="drug drug_general" data-topicid="15575" href="/z/d/drug information/15575.html" rel="external">denosumab</a> therapy to date. Furthermore, histologic examination of MRONJ lesions demonstrates patent vessels in the majority of cases [<a href="#rid17">17,18</a>]. Thus, it seems unlikely that MRONJ represents a form of avascular necrosis. (See <a class="local">'Concurrent antineoplastic therapy'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The preferential localization of MRONJ events to the mandible suggests that the more frequent microdamage inflicted on the lower jaw bone with mastication might also represent a contributory factor [<a href="#rid19">19</a>]. However, approximately one-third of cases occur in the maxillary bone. (See <a class="local">'Clinical presentation'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Local oral risk factors have been implicated in MRONJ pathogenesis. Histopathologic findings implicate bone necrosis and infection, although it is not clear which is primary [<a href="#rid20">20</a>]. Although tooth extraction had been performed in most of the initial reported cases of bisphosphonate-related MRONJ, these teeth commonly had preexisting periodontal or periapical disease. Animal models indicate that both inflammation/bacterial infection and systemic administration of osteoclast inhibitors are sufficient to induce MRONJ [<a href="#rid21">21-23</a>]. (See <a class="local">'Oral health-associated risk factors'</a> below.)</p><p></p><p class="bulletIndent1">Complex biofilms have been identified on the bone/tooth and mucosal surfaces around bisphosphonate-related MRONJ that are composed of actinomyces and other organisms including fungi and viruses [<a href="#rid17">17,24-27</a>]. However, it is not known whether MRONJ represents direct toxicity to the bone and/or soft tissues that becomes secondarily infected [<a href="#rid28">28,29</a>] or if a primary infection is subsequently exacerbated by the use of osteoclast inhibitors. Furthermore, it is unclear if the common presence of actinomyces in these lesions is actively contributing to the development or progression of MRONJ or is simply related to the presence of necrotic bone in an anaerobic environment [<a href="#rid24">24</a>]. Controlled trials evaluating specific antimicrobials or therapy for actinomycosis in MRONJ have not been performed; however, antimicrobial therapy is a hallmark of all therapy for MRONJ to decrease surrounding inflammation and oral pain [<a href="#rid26">26</a>].</p><p></p><p class="bulletIndent1">A central role for local monocytes and macrophages has been proposed as a unifying hypothesis to explain a link between infection (which increases macrophage recruitment to the mucosa of the oral cavity [<a href="#rid30">30</a>]) and the use of osteoclast inhibitors such as bisphosphonates or <a class="drug drug_general" data-topicid="15575" href="/z/d/drug information/15575.html" rel="external">denosumab</a> (which have a detrimental effect on macrophages, compromising the local immune response [<a href="#rid20">20,31</a>]), which sets the stage for subsequent bone destruction [<a href="#rid11">11</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Accumulating evidence on risk factors for MRONJ in patients undergoing therapy with an osteoclast inhibitor (which include concomitant use of antiangiogenic therapies) supports the view that MRONJ is a multifactorial process with contributions from impaired bone repair and suppression of osteoclast activity; impaired angiogenesis or vascular repair; and local factors, such as poor dental hygiene, advanced periodontal disease, poorly fitting dentures, and/or a dental manipulation of some sort (eg, dental extraction) [<a href="#rid28">28,32-38</a>].</p><p></p><p class="headingAnchor" id="H664776076"><span class="h1">CLINICAL PRESENTATION</span><span class="headingEndMark"> — </span>Areas of exposed and necrotic bone, which may remain asymptomatic for weeks, months, or even years, are the consistent hallmark of MRONJ [<a href="#rid39">39</a>]. The lesions may become symptomatic when the surrounding soft tissues become inflamed. Signs and symptoms that may occur before the development of clinically detectable osteonecrosis include prolonged jaw pain, tooth mobility, bone enlargement, gingival swelling, erythema, and ulceration [<a href="#rid24">24,39,40</a>].These may occur spontaneously or at the site of prior dental surgery. The size of the affected area is variable and may range from a nonhealing tooth extraction site to a large section of the jawbone.</p><p>Intraoral or extraoral fistula(e) may develop when the necrotic bone becomes secondarily infected. The clinical scenario may resemble osteomyelitis. Chronic maxillary sinusitis is sometimes the presenting symptom in patients with maxillary bone involvement. Finally, some patients may present with altered sensation in the affected area due to compression of the neurovascular bundle by the inflamed surrounding bone.</p><p>The location of MRONJ is more often mandibular than maxillary (2:1 ratio), but can appear in both jaws [<a href="#rid41">41,42</a>]. In one review of 368 reported cases, MRONJ was manifested in the mandible in 65 percent, maxilla in 26 percent, and both in 9 percent [<a href="#rid41">41</a>].</p><p>Several clinical staging systems are available that can help to categorize patients according to severity and direct rational treatment. (See <a class="local">'Staging and treatment'</a> below.)</p><p class="headingAnchor" id="H664782433"><span class="h2">Imaging studies</span><span class="headingEndMark"> — </span>Screening radiographic studies are often recommended to define current dental disease that may be a risk factor for MRONJ development and thus should be treated prior to the initiation of osteoclast inhibitor therapies.</p><p>The radiographic features of MRONJ are relatively nonspecific [<a href="#rid43">43</a>]. MRONJ can be visualized using panoramic radiography, cone beam computed tomography (CT; to limit radiation doses) [<a href="#rid44">44</a>], or magnetic resonance imaging (MRI) [<a href="#rid45">45</a>]. However, the extent of these lesions may not be clear, especially in the early stages. In particular, radiographic findings such as poorly healing or nonhealing extraction sockets, periapical radiolucencies, and widening of the periodontal ligament space are not specific in the early stages of the disease [<a href="#rid46">46</a>].</p><p>CT is more sensitive than plain radiographs to changes in bone mineralization and therefore, more likely to demonstrate areas of focal sclerosis, thickened lamina dura, early sequestrum formation, and the presence of reactive periosteal bone [<a href="#rid39">39</a>]. Delineation of the extent of the diseased area by CT may be helpful for surgical treatment planning.</p><p>Early studies demonstrating increased radiotracer uptake in regions of the jaws that subsequently developed necrosis suggest potential utility for nuclear bone scanning in patients at risk for MRONJ [<a href="#rid47">47,48</a>]. Its usefulness as a predictive tool for patients with stage 0 disease  (<a class="graphic graphic_table graphicRef96868" href="/z/d/graphic/96868.html" rel="external">table 1</a>) merits continued evaluation.</p><p class="headingAnchor" id="H664782439"><span class="h2">Differential diagnosis</span><span class="headingEndMark"> — </span>The differential diagnosis of MRONJ includes alveolar osteitis, sinusitis, gingivitis/periodontitis, caries, periapical pathology (periodontal abscess, necrotic dental pulp with apical abscess), sarcoma, chronic sclerosing osteomyelitis (proliferative periostitis), and temporomandibular joint disorders [<a href="#rid49">49</a>]. In those rare situations where patients have been exposed to both radiation therapy and either an osteoclast inhibitor or an antiangiogenic agent, osteoradionecrosis should also be strongly considered. (See  <a class="medical medical_review" href="/z/d/html/3365.html" rel="external">"Management of late complications of head and neck cancer and its treatment", section on 'Osteoradionecrosis and soft tissue necrosis'</a> and  <a class="medical medical_review" href="/z/d/html/16346.html" rel="external">"Oral health in cancer survivors", section on 'Osteonecrosis'</a> and  <a class="medical medical_review" href="/z/d/html/3416.html" rel="external">"Complications, diagnosis, and treatment of odontogenic infections"</a> and  <a class="medical medical_review" href="/z/d/html/5629.html" rel="external">"Temporomandibular disorders in adults"</a> and  <a class="medical medical_review" href="/z/d/html/6871.html" rel="external">"Acute sinusitis and rhinosinusitis in adults: Clinical manifestations and diagnosis"</a> and  <a class="medical medical_review" href="/z/d/html/7528.html" rel="external">"Chronic rhinosinusitis: Clinical manifestations, pathophysiology, and diagnosis"</a>.)</p><p class="headingAnchor" id="H664776082"><span class="h1">INCIDENCE AND RISK FACTORS</span></p><p class="headingAnchor" id="H664779873"><span class="h2">Osteoclast inhibitor therapy</span><span class="headingEndMark"> — </span>Although potentially serious, MRONJ is a relatively uncommon complication of therapy with intravenous bisphosphonates and <a class="drug drug_general" data-topicid="15575" href="/z/d/drug information/15575.html" rel="external">denosumab</a> among patients with advanced malignancy, although it is more common in patients with cancer than in patients who are treated with osteoclast inhibitors for osteoporosis [<a href="#rid50">50</a>]. (See  <a class="medical medical_review" href="/z/d/html/104424.html" rel="external">"Risks of bisphosphonate therapy in patients with osteoporosis", section on 'Osteonecrosis of the jaw'</a> and  <a class="medical medical_review" href="/z/d/html/2067.html" rel="external">"Denosumab for osteoporosis", section on 'Adverse effects'</a>.)</p><p>The best information on incidence in patients with advanced cancer comes from a review of data on 5677 patients with bone metastases from a wide variety of malignancies enrolled on three identically designed prospective randomized trials comparing <a class="drug drug_general" data-topicid="9902" href="/z/d/drug information/9902.html" rel="external">zoledronic acid</a> with <a class="drug drug_general" data-topicid="15575" href="/z/d/drug information/15575.html" rel="external">denosumab</a> for the prevention of skeletal-related events; the most recent data were presented in a preliminary report at the 2013 American Society of Clinical Oncology (ASCO) meeting and were updated with data from the open-label extension phase of the trials in breast and prostate cancer patients [<a href="#rid42">42,51,52</a>]. MRONJ was defined per the 2009 guidelines of the American Association of Maxillofacial Surgeons (AAOMS) [<a href="#rid53">53</a>].</p><p>The following findings were noted:</p><p class="bulletIndent1"><span class="glyph">●</span>All patients were treated monthly, and the median time to onset of MRONJ was 15 to 16 months [<a href="#rid52">52</a>]. Sixty-three patients (1.9 percent) on the <a class="drug drug_general" data-topicid="15575" href="/z/d/drug information/15575.html" rel="external">denosumab</a> treatment arm developed MRONJ compared with 44 (1.3 percent) on the <a class="drug drug_general" data-topicid="9902" href="/z/d/drug information/9902.html" rel="external">zoledronic acid</a> arm. This difference was not significant between treatment groups (p = 0.08). The cumulative incidence rates of MRONJ increased with longer duration of exposure, with an incidence of 0.7 to 1.4 percent during the first year of therapy and increasing to 2 to 3.4 percent with continued treatment beyond one year [<a href="#rid51">51</a>]. When compared with the risk for MRONJ in the placebo arms of the prior intravenous bisphosphonate studies to prevent complications from skeletal metastases (range 0 to 0.19 percent [<a href="#rid54">54-56</a>]), the risk of MRONJ was 50- to 100-fold higher with the use of modern high-dose monthly intravenous bisphosphonates (ie, zoledronic acid 4 mg monthly) [<a href="#rid42">42</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Dental extraction preceded the MRONJ event in 63 percent of cases; 82 percent had jaw pain, and a coincident oral infection was present in 48 percent of cases. (See <a class="local">'Dentoalveolar surgery'</a> below.)</p><p></p><p class="headingAnchor" id="H664776088"><span class="h3">Dose, duration, and type of therapy</span></p><p class="headingAnchor" id="H664776094"><span class="h4">Bisphosphonates</span><span class="headingEndMark"> — </span>The potency of the bisphosphonate, frequency of administration, and duration of use influence MRONJ risk:</p><p class="bulletIndent1"><span class="glyph">●</span>The risk is higher with intravenous than with oral bisphosphonates and most commonly observed in patients receiving intensive (monthly) parenteral dosing for prevention of skeletal-related events [<a href="#rid57">57-59</a>]. The incidence of MRONJ observed with osteoporosis dosing of bisphosphonates is markedly lower compared with that observed in oncology patients.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The incidence is higher with longer duration of treatment, particularly when the duration of therapy exceeds four years [<a href="#rid3">3,32,60,61</a>]. This time frame may be shortened by the presence of certain comorbidities, such as chronic glucocorticoid use or concomitant administration of angiogenesis inhibitors. (See <a class="local">'Concurrent antineoplastic therapy'</a> below and <a class="local">'Other risk factors'</a> below.)</p><p></p><p class="bulletIndent1">As an example, in a retrospective series of 3994 patients with malignancy who were receiving intravenous bisphosphonates, the median duration of <a class="drug drug_general" data-topicid="9736" href="/z/d/drug information/9736.html" rel="external">pamidronate</a> use was longer in those who developed MRONJ compared with those who did not (1.68 versus 0.59 years in breast cancer, and 1.55 versus 0.3 years in multiple myeloma [<a href="#rid3">3</a>]). The same findings were noted among patients receiving <a class="drug drug_general" data-topicid="9902" href="/z/d/drug information/9902.html" rel="external">zoledronic acid</a> (2.04 versus 0.73 years in breast cancer, and 1.85 versus 0.67 years in myeloma).</p><p></p><p class="bulletIndent1">The higher risk with longer duration of treatment can be illustrated by results from SWOG S0702, a prospective observational cohort study designed to assess the incidence and risk factors for MRONJ in 3491 patients receiving <a class="drug drug_general" data-topicid="9902" href="/z/d/drug information/9902.html" rel="external">zoledronic acid</a> for bone metastases [<a href="#rid62">62</a>]. The cumulative incidence of MRONJ was 0.8 percent at year 1, 1.2 percent at year 2, and 2.8 percent at year 3.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Chronic treatment with <a class="drug drug_general" data-topicid="9902" href="/z/d/drug information/9902.html" rel="external">zoledronic acid</a> has been implicated as a greater contributor to the development of MRONJ than <a class="drug drug_general" data-topicid="9736" href="/z/d/drug information/9736.html" rel="external">pamidronate</a> [<a href="#rid4">4,25,32,57,60,63-67</a>]. As an example, a web-based survey of 904 patients with multiple myeloma and 299 with breast cancer identified 75 patients with MRONJ and an additional 77 with findings suspicious for early MRONJ [<a href="#rid63">63</a>]. MRONJ developed in 10 and 4 percent of those treated with zoledronic acid or pamidronate, respectively. However, the diagnosis of MRONJ was not necessarily confirmed in individuals who reported having this condition in this web-based survey. In addition, use of zoledronic acid was likely longer than with pamidronate since widespread use of pamidronate occurred during a time in which survival of these patients was much shorter.</p><p></p><p class="bulletIndent1">In the Southwest Oncology Group (SWOG) 0307 trial comparing three bisphosphonates as adjuvant therapy in breast cancer, intravenous <a class="drug drug_general" data-topicid="9902" href="/z/d/drug information/9902.html" rel="external">zoledronic acid</a> was associated with a higher incidence of MRONJ (1.26 percent) compared with oral daily <a class="drug drug_general" data-topicid="8774" href="/z/d/drug information/8774.html" rel="external">clodronate</a> (0.36 percent) and oral daily <a class="drug drug_general" data-topicid="8887" href="/z/d/drug information/8887.html" rel="external">ibandronate</a> (0.77 percent) after three years of therapy [<a href="#rid68">68</a>]. (See  <a class="medical medical_review" href="/z/d/html/776.html" rel="external">"Use of osteoclast inhibitors in early breast cancer"</a>.)</p><p></p><p class="bulletIndent1">The greater risk for MRONJ with <a class="drug drug_general" data-topicid="9902" href="/z/d/drug information/9902.html" rel="external">zoledronic acid</a> is likely due to its greater potency. However, it should be noted that zoledronic acid was administered monthly for six months and then every three months to complete three years of therapy in this trial and that monthly zoledronic acid dosing is no longer recommended for many cancer patients with bone metastases.</p><p></p><p>Whether the incidence of MRONJ might be lowered by extending the dosing interval of bisphosphonates has been addressed in the following studies:</p><p class="bulletIndent1"><span class="glyph">●</span>In CALGB (Alliance) 70604, the largest study addressing dosing interval, 1822 patients with metastatic breast cancer (n = 855), prostate cancer (n = 689), or multiple myeloma (n = 278) and without prior intravenous bisphosphonate therapy were randomized to every-4-week or every-12-week <a class="drug drug_general" data-topicid="9902" href="/z/d/drug information/9902.html" rel="external">zoledronic acid</a> for two years to prevent skeletal-related events [<a href="#rid69">69</a>]. There was no statistically significant difference in the incidence of MRONJ events observed between the two arms; however, 18 patients (2 percent) in the every-four-week dosing, compared with nine patients (1 percent) in the every-12-week dosing, were diagnosed with MRONJ.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In the larger prospective observational SWOG S0702 study, which assessed the cumulative incidence of MRONJ at three years in patients with metastatic bone disease from any malignancy, a much higher risk for MRONJ was observed in those with a planned dosing interval of less than five weeks versus longer (three year cumulative rate 3.2 versus 0.7 percent, hazard ratio 4.65, 95% CI 1.46-14.8) [<a href="#rid62">62</a>].</p><p></p><p>ASCO guidelines on the use of intravenous <a class="drug drug_general" data-topicid="9902" href="/z/d/drug information/9902.html" rel="external">zoledronic acid</a> for the prevention of skeletal-related events in patients with metastatic breast cancer were revised in 2017 to include every 12-week dosing as an option [<a href="#rid70">70</a>]. Although a clear recommendation was not made, to reduce the risk of MRONJ, a once every 12-week dosing is preferred over every 3 to 4 week dosing for most patients with bone metastases from breast or castration-resistant prostate cancer who have neither extensive nor highly symptomatic bone metastases. In 2020, clinical practice guidelines from ESMO recommended 3 to 6 months of monthly zoledronic acid prior to switching to an every 12 week dosing schedule [<a href="#rid71">71</a>]. The rationale for this recommendation included the relatively short follow-up of the largest trial comparing every 4 week to every 12 week zoledronic acid dosing, an increased incidence of serious skeletal-related events with the 12 week dosing, no difference in ONJ events with the longer dosing schedule, and the concern of several experts on the consensus panel that patients with extensive bone disease may initially require more potent osteoclast inhibition until disease control is obtained. The extended dosing interval applies to metastatic solid tumors but not myeloma. This subject is addressed in detail elsewhere. (See  <a class="medical medical_review" href="/z/d/html/2801.html" rel="external">"Osteoclast inhibitors for patients with bone metastases from breast, prostate, and other solid tumors", section on 'Dosing interval'</a> and  <a class="medical medical_review" href="/z/d/html/6663.html" rel="external">"Multiple myeloma: The use of osteoclast inhibitors", section on 'Should the dose interval/frequency be adjusted?'</a>.)</p><p class="headingAnchor" id="H664776100"><span class="h4">Denosumab</span><span class="headingEndMark"> — </span>As with bisphosphonates, dose, schedule, and duration of osteoclast inhibition are associated with MRONJ risk in patients treated with <a class="drug drug_general" data-topicid="15575" href="/z/d/drug information/15575.html" rel="external">denosumab</a>. The approved dose of denosumab for prevention of skeletal-related events in patients with bone metastases from solid tumors is 120 mg subcutaneously every four weeks. At this dose, the risk of MRONJ is consistently slightly higher than that seen with intravenous bisphosphonates, but the difference has not been statistically significant in any individual trial:</p><p class="bulletIndent1"><span class="glyph">●</span>In an integrated analysis of patient-level information from all three registration trials, which were conducted identically with the only difference being the tumor type (ie, breast, prostate, or other solid tumors), the risk of MRONJ with <a class="drug drug_general" data-topicid="15575" href="/z/d/drug information/15575.html" rel="external">denosumab</a> was slightly higher, but the difference was not statistically significant (1.9 versus 1.3 percent, p = 0.08) [<a href="#rid52">52</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In the phase III clinical trial comparing <a class="drug drug_general" data-topicid="15575" href="/z/d/drug information/15575.html" rel="external">denosumab</a> with <a class="drug drug_general" data-topicid="9902" href="/z/d/drug information/9902.html" rel="external">zoledronic acid</a> in 1718 patients with newly diagnosed multiple myeloma, 4.1 percent of patients receiving denosumab compared with 2.8 percent of patients receiving zoledronic acid developed MRONJ after a median drug exposure of 16 and 15 months, respectively [<a href="#rid72">72</a>]. (See  <a class="medical medical_review" href="/z/d/html/6663.html" rel="external">"Multiple myeloma: The use of osteoclast inhibitors"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In the most recent meta-analysis of five randomized trials of <a class="drug drug_general" data-topicid="15575" href="/z/d/drug information/15575.html" rel="external">denosumab</a> versus bisphosphonates (which included the three registration trials plus two others, both of which used different dose/schedules of administration for denosumab and neither of which prospectively evaluated MRONJ as an endpoint), the rate of MRONJ was again higher with denosumab, but the difference was not statistically significant (1.7 versus 1.1 percent, RR 1.48, 95% CI 0.96-2.29) [<a href="#rid54">54</a>]. Nevertheless, MRONJ rates were consistently higher among denosumab-treated compared with zoledronic-acid-treated patients from individual trials.</p><p></p><p>When <a class="drug drug_general" data-topicid="15575" href="/z/d/drug information/15575.html" rel="external">denosumab</a> has been administered at a significantly lower dose (ie, 60 mg subcutaneously every six months) for the treatment of postmenopausal or cancer therapy-related osteoporosis, MRONJ rates are less than 1 percent for up to five years of therapy [<a href="#rid73">73</a>]. (See  <a class="medical medical_review" href="/z/d/html/2067.html" rel="external">"Denosumab for osteoporosis", section on 'Adverse effects'</a>.)</p><p>As with bisphosphonates, duration of therapy influences risk, although at least some data support the view that risk plateaus between years 2 and 3 [<a href="#rid42">42,74</a>]. As an example, in an analysis of the three phase III registration trials, the incidence of developing MRONJ was 1.1 percent during the first year and 4.1 percent thereafter [<a href="#rid52">52</a>].</p><p>There are only limited data addressing less frequent dosing than every four weeks for <a class="drug drug_general" data-topicid="15575" href="/z/d/drug information/15575.html" rel="external">denosumab</a>, and this approach cannot yet be recommended. However, on a case-by-case basis, every-12-week dosing may be appropriate for informed and selected patients with bone metastases from breast cancer or castration-resistant prostate cancer. (See  <a class="medical medical_review" href="/z/d/html/2801.html" rel="external">"Osteoclast inhibitors for patients with bone metastases from breast, prostate, and other solid tumors", section on 'Dosing interval'</a>.)</p><p class="headingAnchor" id="H664780180"><span class="h3">Concurrent antineoplastic therapy</span><span class="headingEndMark"> — </span>The incidence appears to be higher among patients with bone metastases who are receiving therapy with an antiangiogenic agent plus an osteoclast inhibitor for prevention of skeletal-related events [<a href="#rid4">4,75-82</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>In a retrospective analysis of 3560 patients receiving bevacizumab-containing therapy for advanced breast cancer from two double-blind, randomized trials and a large, nonrandomized safety study, there was a trend towards increased MRONJ in those who received bisphosphonates (0.9 versus 0.2 percent) in the analysis of the pooled, randomized trials (n = 1309 patients) and 2.4 versus 0 percent in the analysis from the nonrandomized safety study (n = 2251 patients) [<a href="#rid75">75</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In another report, 11 of 60 (18.3 percent) patients with metastatic castration-resistant prostate cancer administered <a class="drug drug_general" data-topicid="8683" href="/z/d/drug information/8683.html" rel="external">bevacizumab</a>, <a class="drug drug_general" data-topicid="9381" href="/z/d/drug information/9381.html" rel="external">docetaxel</a>, <a class="drug drug_general" data-topicid="10095" href="/z/d/drug information/10095.html" rel="external">thalidomide</a>, and <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">prednisone</a> with concurrent <a class="drug drug_general" data-topicid="9902" href="/z/d/drug information/9902.html" rel="external">zoledronic acid</a> developed MRONJ [<a href="#rid79">79</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In a retrospective review of 90 patients treated with concomitant oral vascular endothelial growth factor (VEGF) receptor tyrosine kinase inhibitors and osteoclast inhibitors, the incidence of MRONJ was 11 percent; during the first year of exposure, the risk was 6.7 percent, compared with 1.1 percent in the control group receiving osteoclast inhibitors alone [<a href="#rid82">82</a>]. MRONJ occurred earlier in patients treated concomitantly compared with those receiving osteoclast inhibitors alone (onset after a median exposure of 4.5 versus 25 months).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Interestingly, other reports have failed to find an association with coadministration of <a class="drug drug_general" data-topicid="10095" href="/z/d/drug information/10095.html" rel="external">thalidomide</a>, which has antiangiogenic as well as immunomodulatory properties [<a href="#rid24">24,32,60,66,83-85</a>].</p><p></p><p>MRONJ is also reported as a side effect in patients receiving antiangiogenic agents as monotherapy. (See <a class="local">'Other medications'</a> below.)</p><p>Concomitant use of anthracyclines may be a risk factor for MRONJ in myeloma patients treated with intravenous bisphosphonates [<a href="#rid86">86</a>].</p><p>Questions remain as to whether glucocorticoids play a similarly important role in the development of MRONJ as they do in the development of osteonecrosis at sites other than the jaw. The data are conflicting, with one series reporting use of glucocorticoids as a risk factor for MRONJ in patients with multiple myeloma and another failing to confirm this finding in patients with multiple myeloma or breast cancer [<a href="#rid3">3,87</a>]. In the large series of patients enrolled in trials comparing <a class="drug drug_general" data-topicid="9902" href="/z/d/drug information/9902.html" rel="external">zoledronic acid</a> with <a class="drug drug_general" data-topicid="15575" href="/z/d/drug information/15575.html" rel="external">denosumab</a> described above, concomitant use of glucocorticoids was observed in 73 percent of those<strong> </strong>who developed MRONJ compared with 62 percent of those who did not [<a href="#rid42">42</a>]. (See  <a class="medical medical_review" href="/z/d/html/122049.html" rel="external">"Clinical manifestations and diagnosis of osteonecrosis (avascular necrosis of bone)", section on 'Glucocorticoids'</a>.)</p><p class="headingAnchor" id="H1957138894"><span class="h2">Other medications</span><span class="headingEndMark"> — </span>There are an increasing number of reports of MRONJ in patients treated with a variety of antineoplastic medications without concurrent use of an osteoclast inhibitor, including angiogenesis inhibitors, inhibitors of the mechanistic (previously called mammalian) target of rapamycin (mTOR), BRAF inhibitors, and immunotherapy; most cases are in patients receiving angiogenesis inhibitors. In a review of 42 MRONJ cases reported in the literature related to non-osteoclast inhibitor therapy, 31 were in patients receiving angiogenesis inhibitors, alone or in combination [<a href="#rid88">88</a>]. (See  <a class="medical medical_review" href="/z/d/html/86366.html" rel="external">"Non-cardiovascular toxicities of molecularly targeted antiangiogenic agents", section on 'Osteonecrosis of the jaw'</a>.)</p><p class="headingAnchor" id="H664776106"><span class="h2">Oral health-associated risk factors</span><span class="headingEndMark"> — </span>Local risk factors, such as invasive dental procedures or concomitant oral disease increase risk for MRONJ [<a href="#rid3">3,32,42,60,63,64,89-91</a>].</p><p class="headingAnchor" id="H934890320"><span class="h3">Dentoalveolar surgery</span><span class="headingEndMark"> — </span>Dentoalveolar surgery is a major risk factor for MRONJ, although cases can occur spontaneously without a precipitating oral event.</p><p>Among patients with MRONJ, 52 to 65 percent report tooth extraction as the predisposing event [<a href="#rid42">42,92,93</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>In a case-control study of 60 cancer patients exposed to <a class="drug drug_general" data-topicid="9902" href="/z/d/drug information/9902.html" rel="external">zoledronic acid</a> (20 who developed MRONJ and 40 matched controls who did not), tooth extraction during bisphosphonate therapy was associated with a significant 16-fold increased risk for MRONJ [<a href="#rid90">90</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In a longitudinal cohort study of 1621 cancer patients exposed to intravenous bisphosphonates, a history of dental extraction was associated with a significant 33-fold (95% CI 18-60) increased risk for MRONJ [<a href="#rid92">92</a>].</p><p></p><p>The best estimate of the absolute risk of developing MRONJ following tooth extraction among cancer patients exposed to osteoclast inhibitors in retrospective studies is as high as 14.8 percent [<a href="#rid94">94</a>], but data from prospective trials suggest that the actual risk is lower, 1.6 to 2.8 percent [<a href="#rid95">95,96</a>]. The risk of developing MRONJ among patients exposed to osteoclast inhibitors for other invasive dental procedures, such as dental implant placement and endodontic or periodontal procedures, is unknown. However, the AAOMS committee concluded that the risk is likely comparable to that seen with tooth extraction [<a href="#rid6">6</a>].</p><p class="headingAnchor" id="H934890550"><span class="h3">Concomitant oral disease and other local risk factors</span><span class="headingEndMark"> — </span>Other local risk factors include trauma during intubation, fractures, dentures, preexisting inflammatory dental disease (periodontal disease, periapical pathology such as abscessed teeth), dental caries, and mandibular tori (bone exostosis) [<a href="#rid42">42,62,89-92,97</a>].</p><p>The incidence of MRONJ may be decreasing as a result of better oral care and recognition of the increased risk from invasive dental procedures among patients receiving these drugs, as well as emphasis on regular dental exams and ongoing dental hygiene in patients receiving these agents. (See <a class="local">'Prevention'</a> below.)</p><p class="headingAnchor" id="H664776112"><span class="h2">Other risk factors</span><span class="headingEndMark"> — </span>The incidence of MRONJ may vary according to the population under study [<a href="#rid91">91</a>]. Reports from Greece and Turkey describe a much higher incidence of MRONJ than in Italy and the United States [<a href="#rid4">4,65,98</a>]. The reasons for these differences could include differences in diagnostic criteria for MRONJ in these different regions, as well as genetic factors [<a href="#rid99">99-101</a>]. However, differences in dental hygiene and frequency of dental exams may also be major contributing factors to this geographic variation in the occurrence of this complication.</p><p>Genetic factors are receiving increased attention. Several reports describe single nucleotide polymorphisms (SNPs), many located within gene regions associated with bone turnover, collagen formation, or certain metabolic bone diseases, that are associated with the development of MRONJ [<a href="#rid101">101-103</a>]. As an example, in one genome-wide association study (GWAS), inheritance of certain polymorphisms in the <em>RBMS3</em> (RNA-binding motif protein, single strand interacting 3) gene was associated with a nearly sixfold increase in the risk of developing MRONJ [<a href="#rid101">101</a>].</p><p>Tobacco use has been inconsistently reported as a risk factor for MRONJ [<a href="#rid90">90,92,97</a>]. Smoking might represent a confounding factor given that smokers tend to have worse oral hygiene than nonsmokers.</p><p class="headingAnchor" id="H968322801"><span class="h3">Tumor type</span><span class="headingEndMark"> — </span>Tumor type is variably reported as a risk factor for MRONJ:</p><p class="bulletIndent1"><span class="glyph">●</span>In a review of data on 5723 patients with bone metastases from a wide variety of malignancies enrolled on three identically designed prospective randomized trials comparing <a class="drug drug_general" data-topicid="9902" href="/z/d/drug information/9902.html" rel="external">zoledronic acid</a> with <a class="drug drug_general" data-topicid="15575" href="/z/d/drug information/15575.html" rel="external">denosumab</a> for the prevention of skeletal-related events, a slightly higher percentage of patients with multiple myeloma developed MRONJ (3.3 percent) versus breast cancer (1.7 percent), prostate cancer (1.8 percent), and other solid tumors (0.9 percent), although only 180 myeloma patients were included in the trials [<a href="#rid42">42</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Other series note a higher risk of MRONJ in myeloma compared with patients who have solid tumors and metastatic bone disease [<a href="#rid3">3,54,60,62,92,104</a>]. As an example, in the S0702 prospective observational cohort study of 3491 patients with bone metastases receiving <a class="drug drug_general" data-topicid="9902" href="/z/d/drug information/9902.html" rel="external">zoledronic acid</a>, cumulative incidence of MRONJ at three years was highest for patients with myeloma (n = 702, 4.3 percent) and lowest for those with breast cancer (2.4 percent) [<a href="#rid62">62</a>].</p><p></p><p class="headingAnchor" id="H664776118"><span class="h1">STAGING AND TREATMENT</span><span class="headingEndMark"> — </span>A well-established staging system should be used to quantify the severity and extent of MRONJ and to guide management decisions [<a href="#rid7">7</a>]. Options include the following:</p><p class="bulletIndent1"><span class="glyph">●</span>The 2014 American Association of Maxillofacial Surgeons (AAOMS) position paper provided a revised clinical staging system to describe the severity of MRONJ [<a href="#rid6">6</a>], which was upheld in the 2022 publication [<a href="#rid8">8</a>]. However, the suggested stage-specific treatment strategies are not evidence based, and in particular, stage 0 disease is not universally accepted [<a href="#rid7">7,9</a>]. Year 2019 guidelines from the Multinational Association of Supportive Care in Cancer (MASCC)/International Society of Oral Oncology (ISOO)/American Society of Clinical Oncology (ASCO) suggest that stage 0 be considered an indicator of increased risk of MRONJ, which could prompt referral to a dental specialist for close follow-up [<a href="#rid7">7</a>]. The various stages and suggested stage-specific treatment strategies are outlined in the table  (<a class="graphic graphic_table graphicRef96868" href="/z/d/graphic/96868.html" rel="external">table 1</a>). </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Common Terminology Criteria for Adverse Events (CTCAE) v5.0  (<a class="graphic graphic_table graphicRef121995" href="/z/d/graphic/121995.html" rel="external">table 2</a>).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Year 2015 International Task Force on Osteonecrosis of the Jaw staging system for MRONJ  (<a class="graphic graphic_table graphicRef121997" href="/z/d/graphic/121997.html" rel="external">table 3</a>) [<a href="#rid9">9</a>].</p><p></p><p>Staging should be performed by a clinician who is experienced with the management of MRONJ, and the same system should be used throughout the patient's MRONJ course and care [<a href="#rid7">7</a>].</p><p class="headingAnchor" id="H664781102"><span class="h2">Treatment goals</span><span class="headingEndMark"> — </span>The major goals of treatment for patients at risk of developing or who have MRONJ are [<a href="#rid6">6</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Prioritization and support of continued oncologic treatment</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Preservation of quality of life through patient education and reassurance, control of pain and secondary infection, and prevention of extension and development of new areas of necrosis</p><p></p><p class="headingAnchor" id="H664781129"><span class="h2">Management strategies</span><span class="headingEndMark"> — </span>Patients should be counseled regarding the possible occurrence of MRONJ prior to initiating therapy with an osteoclast inhibitor or antiangiogenic agent.</p><p class="headingAnchor" id="H664780842"><span class="h3">Prevention</span></p><p class="headingAnchor" id="H1184707601"><span class="h4">Before initiation of an intravenous osteoclast inhibitor</span><span class="headingEndMark"> — </span>In view of the difficulty in treating established MRONJ, prevention is emphasized.</p><p>We agree with joint guidelines from the MASCC/ISOO/ASCO as well as guidelines from the AAOMS, the International Task Force on Osteonecrosis of the Jaw, the European Medicines Agency (EMA), and the American Academy of Oral Medicine, which all recommend that all patients have a comprehensive dental, periodontal, and oral radiographic examination (when feasible to do so) and preventive dentistry (preemptive extraction of unsalvageable teeth and optimized periodontal health) before beginning therapy with an osteoclast inhibitor [<a href="#rid6">6,7,9,105-109</a>]. Oral care should be provided by a dentist or dental professional who is familiar with cancer therapies and their expected adverse effects and is committed to integrating oral care with cancer therapy [<a href="#rid110">110</a>]. Based on the assessment, a dental care plan should be developed, implemented, and coordinated between the dental specialist and the oncologist to ensure that medically necessary dental procedures are undertaken before the initiation of the osteoclast inhibitor.</p><p>The components of a complete evaluation should include the following [<a href="#rid6">6,7</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Nonrestorable teeth and those that are not likely to be salvageable should be extracted. If systemic conditions permit, initiation of therapy with the osteoclast inhibitor or antiangiogenic agent should be delayed until the extraction site is mucosalized (14 to 21 days) or until there is adequate osseous healing. These decisions should be made jointly by the treating clinician and dentist.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Whenever possible, minor dental procedures with preservation of the dental root are preferred over total tooth extraction.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Active oral infections should be treated, and sites at high risk for infection should be eliminated.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Dental prophylaxis, caries control, and conservative restorative dentistry are critical to maintaining functionally sound teeth.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Patients with full or partial dentures should be examined for areas of mucosal trauma.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Patients must be educated as to the importance of dental hygiene and regular dental evaluations, and instructed to report promptly any oral pain, swelling, or exposed bone. Use of a systematic daily oral care plan  (<a class="graphic graphic_table graphicRef121987" href="/z/d/graphic/121987.html" rel="external">table 4</a>) should be highly encouraged [<a href="#rid7">7</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Modifiable risk factors for MRONJ (eg, poor oral health, ill-fitting dentures, uncontrolled diabetes, and tobacco use) should be addressed as early as possible. (See <a class="local">'Incidence and risk factors'</a> above.)</p><p></p><p>Performing the medically necessary dental care in this context may not be feasible if the patient's medical condition warrants prompt initiation of the osteoclast inhibitor (eg, rapidly progressive bone disease or acute hypercalcemia, for which the benefits of prompt initiation of an osteoclast inhibitor outweigh the risk for MRONJ). In such cases, partial or minimal evaluation protocols are suggested. Recommended dental evaluation protocols, as derived from a systematic review of dental disease management in cancer patients [<a href="#rid111">111</a>], are outlined in the table  (<a class="graphic graphic_table graphicRef121989" href="/z/d/graphic/121989.html" rel="external">table 5</a>).</p><p>Follow-up by the dentist should then be performed on a routine schedule (eg, every six months) once therapy with an osteoclast inhibitor has commenced [<a href="#rid7">7</a>].</p><p>One single open-label randomized trial [<a href="#rid112">112</a>] provides some evidence, albeit of very low quality [<a href="#rid113">113</a>], that periodic dental examinations and preventive treatments may be more effective than standard care for reducing the incidence of MRONJ, although benefit from dental screening and prophylactic treatment is also supported by retrospective single-institution studies [<a href="#rid114">114-119</a>]. This study randomized 253 men with prostate cancer and bone metastases receiving intravenous <a class="drug drug_general" data-topicid="9902" href="/z/d/drug information/9902.html" rel="external">zoledronic acid</a> therapy to regular dental visits every three months versus standard of care dental delivery [<a href="#rid112">112</a>]. All patients received baseline dental visits and preventive dentistry prior to initiating bisphosphonate therapy. The primary endpoint was the incidence of MRONJ, defined as nonhealing exposed bone in the mandible or maxilla for greater than eight weeks. A 2.2 percent incidence of MRONJ was observed in the experimental arm versus 23.3 percent in the standard arm. However, the study was flawed by a high and unbalanced rate of crossover from the experimental arm to the standard arm and the data being presented "as treated" rather than in an "intention-to-treat" analysis; this led to a very low certainty of evidence grade for this trial in a Cochrane Database Review of interventions for MRONJ [<a href="#rid113">113</a>].</p><p class="headingAnchor" id="H1184707614"><span class="h4">Asymptomatic patients during therapy</span><span class="headingEndMark"> — </span>During therapy with an osteoclast inhibitor or antiangiogenic agent, oral hygiene status should be closely monitored. All patients should practice good oral hygiene, including daily brushing, flossing, and use of antibacterial oral rinses, and attending recommended dental check-ups, denture fittings, and routine cleanings  (<a class="graphic graphic_table graphicRef121987" href="/z/d/graphic/121987.html" rel="external">table 4</a>), to decrease rates of periodontal disease and oral infection. Invasive dental procedures should be avoided, if possible. Patients should be encouraged to stop smoking and curtail alcohol [<a href="#rid46">46</a>]. (See <a class="local">'Other risk factors'</a> above.)</p><p>Patients should be asked about possible planned dental procedures prior to administration of each dose of the osteoclast inhibitor and reminded to avoid invasive dental procedures (dental extractions, implants, and any other procedures that involve manipulation of the jaw bone or periosteum) while being treated with these drugs. Patients should be reassured that relatively noninvasive dental procedures such as dental cleaning, repair of cavities, placement of crowns or "caps," and even routine root canals do not increase the risk of MRONJ.</p><p>Efforts to establish risk assessment by measuring fluctuations in bone turnover markers during therapy remain controversial [<a href="#rid120">120-122</a>]. These markers are a reflection of bone turnover throughout the entire skeleton and are not specific to the jaws where bone turnover rate is severely suppressed beyond other bone sites.</p><p class="headingAnchor" id="H1184708100"><span class="h4">Lengthening the dosing interval of the osteoclast inhibitor</span><span class="headingEndMark"> — </span>Every-four-week administration of bisphosphonates represents a standard approach, although, as noted above, the available evidence is now sufficient to support dosing <a class="drug drug_general" data-topicid="9902" href="/z/d/drug information/9902.html" rel="external">zoledronic acid</a> every 12 weeks rather than every 4 weeks in most patients with bone metastases from breast or castration-resistant prostate cancer who have neither extensive nor highly symptomatic bone metastases. (See <a class="local">'Bisphosphonates'</a> above and  <a class="medical medical_review" href="/z/d/html/2801.html" rel="external">"Osteoclast inhibitors for patients with bone metastases from breast, prostate, and other solid tumors", section on 'Dosing interval'</a>.)</p><p>In view of the demonstration of improved overall survival among previously untreated myeloma patients receiving monthly <a class="drug drug_general" data-topicid="9902" href="/z/d/drug information/9902.html" rel="external">zoledronic acid</a> compared with daily oral <a class="drug drug_general" data-topicid="8774" href="/z/d/drug information/8774.html" rel="external">clodronate</a> in the Medical Research Council Myeloma IX trial, many clinicians do not advocate less frequent dosing of bisphosphonates for patients with myeloma in order to reduce the risk of MRONJ. This trial is discussed in detail elsewhere. (See  <a class="medical medical_review" href="/z/d/html/6663.html" rel="external">"Multiple myeloma: The use of osteoclast inhibitors", section on 'Long-term management'</a>.)</p><p>On the other hand, there are only limited data addressing the efficacy of less frequent dosing of <a class="drug drug_general" data-topicid="15575" href="/z/d/drug information/15575.html" rel="external">denosumab</a>, and every-four-week administration remains the standard approach. (See <a class="local">'Denosumab'</a> above and  <a class="medical medical_review" href="/z/d/html/2801.html" rel="external">"Osteoclast inhibitors for patients with bone metastases from breast, prostate, and other solid tumors", section on 'Dosing interval'</a>.)</p><p class="headingAnchor" id="H1098730857"><span class="h4">Cessation of at-risk medication prior to invasive dental procedures</span><span class="headingEndMark"> — </span>Elective dentoalveolar surgical procedures should be avoided, if at all possible, during treatment with an osteoclast inhibitor. (See <a class="local">'Asymptomatic patients during therapy'</a> above.)</p><p>Exceptions may be considered when a dental specialist with expertise in the prevention and management of MRONJ has reviewed the benefits and risks of the proposed invasive procedure with the patient and the oncology team [<a href="#rid7">7</a>]. Decisions about whether to continue the osteoclast inhibitor following the surgical procedure must be individualized. If dentoalveolar surgery is performed, patients should be evaluated by the dental specialist on a systematic and frequent basis (eg, every six to eight weeks) until full mucosal coverage at the surgical site has occurred. Communication with the oncology team about the status of healing  (<a class="graphic graphic_table graphicRef121984" href="/z/d/graphic/121984.html" rel="external">table 6</a>) is encouraged, particularly when considering future use of an osteoclast inhibitor.</p><p>The optimal management of a patient who requires an invasive dental procedure (eg, tooth extraction, dental implant procedure, or apical endodontic treatment) during treatment with an osteoclast inhibitor or antiangiogenic agent is not established, and there are scant data to guide the clinician in this setting. Updated 2019 guidelines from the MASCC/ISOO/ASCO state that there is insufficient evidence to support or refute the need for discontinuation of the osteoclast inhibitor before dentoalveolar surgery [<a href="#rid7">7</a>]. Administration of the osteoclast inhibitor may be deferred at the discretion of the treating clinician, in conjunction with a discussion with the patient and the oral health provider.</p><p>In the absence of data, it may also be reasonable to hold the osteoclast inhibitor for two to three months before and after the procedure and to restart once the mucosa is completely healed over, if doing so is consistent with the oncologic goals of care.</p><p class="headingAnchor" id="H1046878455"><span class="h4">Local instillation of plasma rich in growth factors</span><span class="headingEndMark"> — </span>One randomized trial compared the use of a plasma rich in growth factors (PRGF) preparation instilled in the postextraction alveolus with a control group treated without PRGF after dental extractions [<a href="#rid95">95</a>]. All patients also received antibiotics for six days starting the day before the extraction. None of the 91 patients treated in the PRGF group developed MRONJ, compared with 5 of the 85 patients in the control group, within a follow-up period of up to 60 months. However, the quality of the evidence presented in this trial has been criticized as very low based on a high risk of bias in patient selection and outcome assessments, and thus, the preventive benefit of PRGF postdental extraction is considered unproven at this time [<a href="#rid113">113</a>].</p><p class="headingAnchor" id="H664781551"><span class="h3">Treatment of established MRONJ</span><span class="headingEndMark"> — </span>Treatment objectives for patients with an established diagnosis of MRONJ are to eliminate pain, control infection of the soft tissue and bone, and minimize the progression or occurrence of bone necrosis. Conservative measures comprise the initial approach to MRONJ [<a href="#rid7">7</a>]. These include antimicrobial mouth rinses, antibiotics (if clinically indicated), effective oral hygiene, and conservative surgical intervention (eg, removal of a superficial bone spicule). Aggressive surgical interventions (eg, mucosal flap elevation, block resection of necrotic bone, or soft tissue closure) may be used if MRONJ results in persistent symptoms or affects function despite initial conservative management. In advance of aggressive surgical intervention, the multidisciplinary care team and patient should discuss the risks and benefits of the proposed intervention.</p><p class="headingAnchor" id="H1184709046"><span class="h4">General approach</span><span class="headingEndMark"> — </span>In general, recommendations for management of MRONJ in patients with cancer are hindered by a lack of data. There are few prospective studies with long-term follow-up with which to guide therapy and no evidence-based guidelines [<a href="#rid113">113</a>]. Nonetheless, treatment has generally shifted away from aggressive surgical interventions to conservative therapy with limited debridement, antibiotics [<a href="#rid7">7,26,123,124</a>], and oral rinses with <a class="drug drug_general" data-topicid="9244" href="/z/d/drug information/9244.html" rel="external">chlorhexidine</a> or <a class="drug drug_general" data-topicid="113931" href="/z/d/drug information/113931.html" rel="external">hydrogen peroxide</a>. Conservative management may result in healing in 30 to 60 percent of cases, although some cases become chronic and develop complications [<a href="#rid25">25,42,125</a>]. (See <a class="local">'Outcomes'</a> below.)</p><p>Microbial cultures from areas of exposed bone will usually isolate normal oral microbes and are not usually helpful. However, when there is extensive soft tissue involvement, microbial cultures may help to define comorbid oral infections, which may guide the selection of an appropriate antibiotic regimen [<a href="#rid39">39</a>].</p><p>Regardless of the stage of disease, areas of necrotic bone that are a source of chronic soft tissue irritation and loose bony sequestra should be removed or recontoured so that soft tissue healing can be optimized [<a href="#rid6">6,126</a>]. The extraction of symptomatic teeth within exposed, necrotic bone should be considered as it appears unlikely that extraction will worsen the established necrotic process. Otherwise, surgical resection of necrotic bone should generally be reserved for refractory or advanced cases [<a href="#rid32">32,127-133</a>]. Resection may occasionally result in even larger areas of exposed and painful infected bone [<a href="#rid25">25,89,127</a>]. When indicated, surgical resection should only be performed by an experienced oral and maxillofacial surgeon [<a href="#rid126">126,134</a>].</p><p class="headingAnchor" id="H1184708693"><span class="h4">Should the at-risk agent be discontinued?</span><span class="headingEndMark"> — </span>There are no prospective data to advise the patient or clinician as to the benefits of discontinuing therapy with the osteoclast inhibitor or antiangiogenic agent in patients who develop MRONJ. While discontinuation of the offending agent might stabilize sites of MRONJ, reduce the risk of developing new sites, and control symptoms, treatment discontinuation could also result in a recurrence of bone pain or an increase in skeletal-related events for patients receiving osteoclast inhibitor therapy in the setting of bone metastases, and a worsening of disease status in patients receiving antiangiogenic agents.</p><p>The decision must be made on a case-by-case basis, taking into account the estimated risks and benefits for the individual patient. There are no prospective trials to prove either strategy.</p><p class="headingAnchor" id="H1184709114"><span class="h5">Osteoclast inhibitors</span><span class="headingEndMark"> — </span>There are no prospective data to advise the patient or clinician as to the benefits of discontinuing therapy with the osteoclast inhibitor, and there is no consensus as to whether it should be discontinued or continued in patients who develop MRONJ. While discontinuation of the offending agent might stabilize sites of MRONJ, reduce the risk of developing new sites, and control symptoms, treatment discontinuation could also result in a recurrence of bone pain or an increase in skeletal-related events for patients receiving an osteoclast inhibitor in the setting of bone metastases, and a worsening of disease status in patients receiving antiangiogenic agents.</p><p>While there is no consensus on this issue, most clinicians, including several of the authors and editors associated with this topic review, discontinue therapy, at least temporarily, and restart after resolution or signs of improvement or stabilization. Because of the rarity of this complication, there is unlikely to be a prospective clinical trial to answer this question. The decision must be made on a case-by-case basis, taking into account the estimated risks and benefits for the individual patient.</p><p>It is unclear whether short-term discontinuation of osteoclast inhibitor therapy is beneficial at stabilizing sites of MRONJ or can improve healing after surgical procedures. Although some reports suggest better outcomes with discontinuation of bisphosphonates for a variable period (one to six months [<a href="#rid135">135,136</a>]), the discontinuation of these agents could also result in a recurrence of bone pain, progression of metastases, and/or an increase in skeletal-related events.</p><p>As bisphosphonates accumulate in the bone matrix and are released over months to years, the rationale for discontinuation of bisphosphonate therapy in patients who develop MRONJ is the interruption of its effects on the oral soft tissues, and specifically the surrounding epithelial cells and fibroblasts and areas of inflammation. <a class="drug drug_general" data-topicid="15575" href="/z/d/drug information/15575.html" rel="external">Denosumab</a>, by contrast, is not accumulated in bone, and its effects on bone are reversible after several months of treatment discontinuation. At present, there are almost no prospective data to advise the patient or clinician as to the benefits of discontinuing therapy with the osteoclast inhibitor once MRONJ develops. In particular, because bisphosphonates have long-term skeletal retention (months to years), it is unclear if stopping treatment for any duration will alter the course of the MRONJ lesion.</p><p>There are anecdotal reports on spontaneous healing of MRONJ in patients receiving conservative therapy even if the osteoclast inhibitor is continued [<a href="#rid42">42,86,89,137,138</a>].</p><p>On the other hand, the benefits of discontinuing therapy in terms of symptom duration were shown in another series of 84 patients with established MRONJ who discontinued bisphosphonate therapy before treatment (n = 21), at the time of presentation of MRONJ (n = 38), or later (or never) in the treatment course (n = 25); patients who continued the bisphosphonate after the start of treatment had a significantly delayed resolution of symptoms compared with those who discontinued the bisphosphonate before or at presentation (median 12 versus 3 and 6 months, respectively) [<a href="#rid136">136</a>]. However, interpretation of these results must be viewed with caution since this was not a randomized study and it is likely that patients with worse MRONJ were more likely the ones that had their bisphosphonates discontinued.</p><p>Not surprisingly, guidelines from expert groups differ:</p><p class="bulletIndent1"><span class="glyph">●</span>The European Myeloma Network suggests discontinuation of bisphosphonates until healing occurs, with treatment restarted if there is cancer progression [<a href="#rid139">139</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Canadian consensus guidelines suggest patient education and review of indications for continued bisphosphonate therapy [<a href="#rid140">140</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A 2022 position paper from the American Association of Oral Maxillofacial Surgeons defines MRONJ and advises that MRONJ is uncommon [<a href="#rid141">141</a>], and that oncology patients should receive antiresorptive agents if indicated, even if they are at risk of developing MRONJ or had MRONJ in the past.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A 2007 ASCO guideline for the role of bisphosphonates in multiple myeloma and a year 2017 guideline on the role of osteoclast inhibitors in metastatic breast cancer provide no guidance as to discontinuation versus continued use of either a bisphosphonate or <a class="drug drug_general" data-topicid="15575" href="/z/d/drug information/15575.html" rel="external">denosumab</a> in patients who develop MRONJ during therapy [<a href="#rid70">70,106</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>This issue was also not specifically addressed in a year 2014 consensus document from the International Task Force on Osteonecrosis of the Jaw [<a href="#rid9">9</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>This issue was addressed in the 2019 joint guidelines from the MASCC/ISOO/ASCO, which stated that there was insufficient evidence to support or refute the discontinuation of the osteoclast inhibitor in this setting [<a href="#rid7">7</a>]. The decision was left to the discretion of the treating clinician, in conjunction with a discussion with the patient and the oral health provider.</p><p></p><p>The US Food and Drug Administration (FDA)-approved manufacturer's package insert for both <a class="drug drug_general" data-topicid="9902" href="/z/d/drug information/9902.html" rel="external">zoledronic acid</a> and <a class="drug drug_general" data-topicid="9736" href="/z/d/drug information/9736.html" rel="external">pamidronate</a> state only that there are no data available to suggest whether discontinuation of bisphosphonate treatment reduces the risk of MRONJ in patients who require dental procedures during therapy and that clinical judgment of the treating clinician should guide the management plan of each patient based on individual benefit/risk assessment [<a href="#rid142">142,143</a>]. The <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fdailymed.nlm.nih.gov%2Fdailymed%2Flookup.cfm%3Fsetid%3D628f0998-1206-4001-aeee-18133aa9f3bf&amp;token=xLEqmdFlfZfJMu8oURyMMXGliOFdMrbtTQibOibmorNPTkPoXUmeuGExB9zX2%2FQ0VnFNaTR6ggJAtS4cwwmUzKsJsjtHuNa6L7iAFrCho80OLdRYunOtw9VFXUWOs1qa&amp;TOPIC_ID=96863" target="_blank">package insert for denosumab</a> does not address the issue of treatment continuation in patients who develop MRONJ.</p><p>Despite these varying guidelines, most oncologists (including several of the authors and editors associated with this topic review) stop or pause osteoclast inhibitor therapy when MRONJ occurs and restart therapy after complete resolution of the lesion. Preventive dentistry and early detection remain the most effective ways to prevent and/or resolve this complication of osteoclast inhibitor therapy. (See <a class="local">'Prevention'</a> above.)</p><p class="headingAnchor" id="H664781589"><span class="h4">Stage-specific management recommendations</span><span class="headingEndMark"> — </span>2019 guidelines on stage-specific management for patients with MRONJ from the MASCC/ISOO/ASCO are presented in the table  (<a class="graphic graphic_table graphicRef96868" href="/z/d/graphic/96868.html" rel="external">table 1</a>) [<a href="#rid7">7</a>].</p><p class="headingAnchor" id="H1561904728"><span class="h4">Nonsurgical treatment strategies</span><span class="headingEndMark"> — </span>Limited data suggest potential benefit for a variety of other nonsurgical treatment strategies, including parathyroid hormone (<a class="drug drug_general" data-topicid="10178" href="/z/d/drug information/10178.html" rel="external">teriparatide</a>), <a class="drug drug_general" data-topicid="9757" href="/z/d/drug information/9757.html" rel="external">pentoxifylline</a>, and <a class="drug drug_general" data-topicid="10049" href="/z/d/drug information/10049.html" rel="external">vitamin E</a>; however, large controlled trials have not yet been performed [<a href="#rid8">8</a>]. Hyperbaric oxygen (HBO) and topical application of medical ozone have also been used as adjunctive therapies for MRONJ, but have not been proven to have efficacy [<a href="#rid7">7</a>].</p><p class="headingAnchor" id="H2083102342"><span class="h5">Teriparatide</span><span class="headingEndMark"> — </span>One small trial suggests potential benefit from a short course of <a class="drug drug_general" data-topicid="10178" href="/z/d/drug information/10178.html" rel="external">teriparatide</a> (recombinant human parathyroid hormone) [<a href="#rid144">144</a>]; similar findings were observed in a retrospective study [<a href="#rid145">145</a>]. However, longer follow-up and larger numbers of treated patients are needed to confirm the safety of teriparatide in this patient population before this treatment can be widely recommended. A short course of teriparatide can be offered to patients who have prolonged, nonhealing MRONJ prior to pursuing aggressive surgical options. The decision to use the drug should be based on an individual risk assessment by the treating clinician together with the patient, balancing the potential for short-term benefit with potential (although likely remote) safety concerns. For those who do not improve with conservative measures, we suggest teriparatide rather than surgery, typically used for a short duration (ie, eight weeks). The decision to use the drug must balance the likelihood of short-term benefit against potential (although likely remote) safety concerns.</p><p><a class="drug drug_general" data-topicid="10178" href="/z/d/drug information/10178.html" rel="external">Teriparatide</a>, a peptide corresponding to the first 34 amino acids of human parathyroid hormone, has been used successfully to treat MRONJ in several case reports of osteoporotic patients, some of whom had atypical femur fractures [<a href="#rid146">146-148</a>]. Teriparatide is thought to improve bone healing by stimulating bone remodeling and growth when given intermittently at low doses [<a href="#rid149">149</a>]. (See  <a class="medical medical_review" href="/z/d/html/2057.html" rel="external">"Parathyroid hormone/parathyroid hormone-related protein analog therapy for osteoporosis"</a>.)</p><p>The benefit of <a class="drug drug_general" data-topicid="10178" href="/z/d/drug information/10178.html" rel="external">teriparatide</a> for MRONJ was directly addressed in a small randomized trial in which 34 patients with exposure to prior bisphosphonates or <a class="drug drug_general" data-topicid="15575" href="/z/d/drug information/15575.html" rel="external">denosumab</a> and who had a diagnosis of MRONJ [<a href="#rid2">2</a>] were randomly assigned to a once per day injection of either placebo or 20 micrograms of teriparatide for eight weeks [<a href="#rid144">144</a>]. All patients received calcium, vitamin D supplementation, and standard clinical care, which included antiseptic mouthwashes, antibiotic therapy, and limited surgical debridement. There were 10 patients with multiple lesions (five in each group), for a total of 47 distinct MRONJ lesions. The indication for antiresorptive therapy was malignant bone disease in 79 percent, and the rest had osteoporosis. Median duration of MRONJ before enrollment was 12 months and similar in both groups. Clinical stage was also similar in both groups; it was 0 or 1 in 13 patients (37 percent of the placebo group versus 40 percent of the teriparatide group), stage 2 in 15 patients (47 versus 46 percent), and stage 3 in 5 patients (16 versus 13 percent)  (<a class="graphic graphic_table graphicRef96868" href="/z/d/graphic/96868.html" rel="external">table 1</a>).</p><p>The following results were noted:</p><p class="bulletIndent1"><span class="glyph">●</span>By 52 weeks, 45 percent of the lesions resolved in the <a class="drug drug_general" data-topicid="10178" href="/z/d/drug information/10178.html" rel="external">teriparatide</a> group and the odds ratio (OR) for resolution at each visit (ie, the proportion of MRONJ-positive sites at each visit) was 0.15 (95% CI 0.07-0.33). In the placebo group, 33 percent of the lesions resolved by week 52, and the OR for resolution at each visit was 0.40 (95% CI 0.22-0.74). Thus, teriparatide was associated with a significantly greater rate of resolution of MRONJ lesions compared with placebo (OR for change over time in the control group 0.40 versus 0.15, p = 0.013).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="10178" href="/z/d/drug information/10178.html" rel="external">Teriparatide</a> was also associated with increased bone volume, and thus, reduced defect size in a greater proportion of patients at 52 weeks (80 versus 31 percent with placebo, OR 8.1, 95% CI 1.36-66.20).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Although the proportion of resolved lesions was higher in the <a class="drug drug_general" data-topicid="10178" href="/z/d/drug information/10178.html" rel="external">teriparatide</a> group, this difference was not statistically significant (OR 1.67, 95% CI 0.41-6.83), nor was there a difference in the proportion of patients with at least one unresolved lesion at 52 weeks (73 versus 72 percent). Furthermore, among those with persistent MRONJ, teriparatide was not associated with a significant improvement in clinical stage.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The incidence of adverse events, including gastrointestinal symptoms, musculoskeletal pain, and injection site reactions, was comparable between the two groups and most were mild. No new malignancies or worsening of preexisting malignancies were reported with <a class="drug drug_general" data-topicid="10178" href="/z/d/drug information/10178.html" rel="external">teriparatide</a>; however, the trial was underpowered and the follow-up limited for these specific safety endpoints.</p><p></p><p>The short duration of this trial is problematic, and it is not yet determined whether treatment with <a class="drug drug_general" data-topicid="10178" href="/z/d/drug information/10178.html" rel="external">teriparatide</a> achieves long-term control of MRONJ. In addition, there are challenges to the use of teriparatide in patients with cancer. There are concerns about the potential for osteosarcoma with prolonged treatment durations when the drug is used long term for treatment of osteoporosis, although these concerns may be unfounded. (See  <a class="medical medical_review" href="/z/d/html/2057.html" rel="external">"Parathyroid hormone/parathyroid hormone-related protein analog therapy for osteoporosis", section on 'Long-term risks'</a>.)</p><p>Another problem is that anabolic treatments such as <a class="drug drug_general" data-topicid="10178" href="/z/d/drug information/10178.html" rel="external">teriparatide</a> are generally not considered viable options for most cancer patients because of generalized concerns about stimulating cellular proliferation (including that of dormant malignant cells) in the bone marrow [<a href="#rid149">149</a>]. As a result, use of this agent in cancer patients remains controversial.</p><p>The data from this small trial, which suggest potential benefit with short duration of <a class="drug drug_general" data-topicid="10178" href="/z/d/drug information/10178.html" rel="external">teriparatide</a> use without any concerning safety signals, are somewhat reassuring. However, longer follow-up and larger numbers of treated patients are needed to confirm the safety of teriparatide in this patient population before we can feel comfortable recommending this treatment widely. In our view, this trial does provide some rationale for offering patients who have prolonged, nonhealing MRONJ an eight-week course of teriparatide prior to pursuing aggressive surgical options. The decision to use the drug should be based on an individual risk assessment by the treating clinician together with the patient, balancing proven benefits with potential (although likely remote) safety concerns.</p><p class="headingAnchor" id="H292715845"><span class="h5">Other strategies</span></p><p class="bulletIndent1"><span class="glyph">●</span>The addition of <a class="drug drug_general" data-topicid="9757" href="/z/d/drug information/9757.html" rel="external">pentoxifylline</a> and oral <a class="drug drug_general" data-topicid="10049" href="/z/d/drug information/10049.html" rel="external">vitamin E</a> to antimicrobial therapy was reported to be effective in a small series of six cases of bisphosphonate-related MRONJ [<a href="#rid150">150</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Benefit for topical application of medical ozone was suggested in a small series of 10 consecutive patients with MRONJ related to bisphosphonate use and in other single case reports from Italy [<a href="#rid151">151-153</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Case reports and small series suggest benefit from HBO [<a href="#rid41">41,154-156</a>]. A small randomized trial of HBO as an adjunct to nonsurgical and surgical treatment of MRONJ in 46 patients demonstrated some improvement in wound healing, pain, and quality of life at three months [<a href="#rid157">157,158</a>]. However, rates of complete gingival coverage, a major study endpoint, were not significantly better with HBO (52 versus 33 percent, p = 0.20), and there were no significant differences when outcomes were assessed at intervals beyond three months.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>There are reports that low-level laser therapy (LLLT) improves healing and symptoms related to MRONJ [<a href="#rid159">159-164</a>]. However, experience is limited to small retrospective series (many of which come from one group in Parma, Italy), and almost all patients received a combination of LLLT with another form of therapy, leaving open the question as to the independent contribution of LLLT [<a href="#rid165">165,166</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Several studies have evaluated the use of autologous platelet concentrates (APC, also called platelet-rich plasma) as an adjunct to oral surgery procedures. One review included 18 studies (392 patients undergoing oral surgery in conjunction with APC), four examining APC for prevention of MRONJ in the setting of tooth extraction and the remainder in conjunction with surgical debridement for treatment of established MRONJ [<a href="#rid167">167</a>]. Excluding one individual case report, of the three studies on tooth extraction, only one was a randomized comparison between APC (n = 91) and no APC (n = 85); in this study, there were five cases of MRONJ in the control group and none in the APC group. However, the quality of the evidence in this trial is considered very low based on a high risk of bias in patient selection and outcome assessments. Among the 14 studies examining the use of therapeutic APC in conjunction with surgical management, four included a group that was treated with APC and a group that was not treated with APC. A meta-analysis of these four studies showed that patients receiving APC had significantly reduced rates of MRONJ recurrence (OR 0.12, 95% CI 0.04-0.36). However, there were only five events in the APC group, compared with 17 in the control group. The authors concluded that the use of APC as an adjunct to oral surgery procedures may be of benefit, although the quality of the evidence is limited, and randomized trials are needed. However, it is not known whether use of APC could have a negative impact on the course of the patient's underlying malignancy.</p><p></p><p class="headingAnchor" id="H2007855316"><span class="h3">Outcomes</span><span class="headingEndMark"> — </span>The clinical course of MRONJ may affect local and/or systemic treatment decisions with respect to cessation or reinitiation of medications, including osteoclast inhibitors. During the course of treatment for MRONJ, the dental specialist should communicate with the medical oncologists the objective and subjective status of the lesion: resolved, improving, stable, or progressive [<a href="#rid7">7</a>]. Proposed terms from the MASCC/ISOO/ASCO clinical practice guideline to characterize MRONJ after treatment are outlined in the table  (<a class="graphic graphic_table graphicRef121984" href="/z/d/graphic/121984.html" rel="external">table 6</a>).</p><p>Some of the best information on outcomes of MRONJ associated with an osteoclast inhibitor comes from a review of data from three identically designed, prospective, randomized trials (described above) comparing <a class="drug drug_general" data-topicid="9902" href="/z/d/drug information/9902.html" rel="external">zoledronic acid</a> with <a class="drug drug_general" data-topicid="15575" href="/z/d/drug information/15575.html" rel="external">denosumab</a> in patients with a wide variety of malignancies [<a href="#rid42">42</a>].</p><p>The majority of patients who developed MRONJ (59 percent) received treatment with oral rinses and/or antibiotics alone, with approximately 40 percent undergoing limited oral surgeries including debridement, sequestrectomy, or extraction. All patients discontinued bone-modifying therapy at MRONJ diagnosis, although six patients treated with <a class="drug drug_general" data-topicid="15575" href="/z/d/drug information/15575.html" rel="external">denosumab</a> reinitiated therapy, and one patient received additional doses of <a class="drug drug_general" data-topicid="9902" href="/z/d/drug information/9902.html" rel="external">zoledronic acid</a> after the diagnosis of MRONJ.</p><p>Of the 52 cases of MRONJ that developed in patients treated with <a class="drug drug_general" data-topicid="15575" href="/z/d/drug information/15575.html" rel="external">denosumab</a>, 21 (40 percent) resolved, 20 (39 percent) were still present at the time of death, eight (15 percent) were ongoing, and three (6 percent) were lost to follow-up at the time of publication. Of the 37 patients who developed MRONJ while receiving <a class="drug drug_general" data-topicid="9902" href="/z/d/drug information/9902.html" rel="external">zoledronic acid</a>, resolution of MRONJ occurred in 11 (30 percent), 15 (41 percent) had MRONJ still present at the time of death, eight (22 percent) had ongoing MRONJ, and three (8 percent) were lost to follow-up at the time of publication. Only one patient received additional doses of zoledronic acid after the diagnosis of MRONJ, and the outcome was not reported. The higher rate of resolution observed with denosumab compared with zoledronic acid in these trials (40 versus 30 percent) may be related to the reversibility of denosumab's effects. In a preliminary report of an updated analysis of this cohort presented at the 2013 ASCO meeting [<a href="#rid52">52</a>], the rate of resolution was 37 percent with denosumab (23 of 63) and 27 percent with zoledronic acid (12 of 44).</p><p>Additional information on the natural history of MRONJ comes from a report of 97 patients with multiple myeloma who were observed prospectively for a minimum of 3.2 years following the diagnosis of MRONJ [<a href="#rid168">168</a>]. Bisphosphonates were stopped once MRONJ was diagnosed. MRONJ resolved in 62 percent, resolved and then recurred in 12 percent, and did not heal in 26 percent.</p><p class="headingAnchor" id="H3503988422"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/z/d/html/120099.html" rel="external">"Society guideline links: Medication-related osteonecrosis of the jaw"</a>.)</p><p class="headingAnchor" id="H664779946"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Definition and clinical features</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Medication-related osteonecrosis of the jaw (MRONJ) is an uncommon but potentially serious side effect that occurs in cancer patients treated with high-potency bisphosphonates or <a class="drug drug_general" data-topicid="15575" href="/z/d/drug information/15575.html" rel="external">denosumab</a>. The pathophysiology is likely multifactorial. (See <a class="local">'Pathophysiology'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Areas of exposed and necrotic bone, which may remain asymptomatic for weeks, months, or even years, are the consistent hallmark of MRONJ. Clinically detectable osteonecrosis may be preceded by prolonged jaw pain, tooth mobility, bone enlargement, gingival swelling, erythema, and/or ulceration. (See <a class="local">'Clinical presentation'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Incidence and risk factors</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Among patients treated with an osteoclast inhibitor for cancer, the incidence of MRONJ is slightly higher with <a class="drug drug_general" data-topicid="15575" href="/z/d/drug information/15575.html" rel="external">denosumab</a> than with bisphosphonates, and it increases with greater treatment duration. Lengthening the interval between treatments from every 4 weeks to every 12 weeks may lower the risk. (See <a class="local">'Incidence and risk factors'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Dentoalveolar surgery is a major risk factor for MRONJ. (See <a class="local">'Dentoalveolar surgery'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Assessing severity and prevention/treatment</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Several clinical staging systems for MRONJ with stage-specific treatment recommendations are available, including one from the American Association of Oral and Maxillofacial Surgeons (AAOMS)  (<a class="graphic graphic_table graphicRef96868" href="/z/d/graphic/96868.html" rel="external">table 1</a>) and one from an international consensus group  (<a class="graphic graphic_table graphicRef121997" href="/z/d/graphic/121997.html" rel="external">table 3</a>). (See <a class="local">'Staging and treatment'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>In view of the difficulty in treating established MRONJ, prevention is emphasized:</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Modifiable risk factors for MRONJ (eg, poor oral health, ill-fitting dentures, uncontrolled diabetes, and tobacco use) should be addressed as early as possible.</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Patients being considered for therapy with an osteoclast inhibitor should be examined by a dentist prior to treatment initiation and needed dental work (eg, removal of unsalvageable teeth and optimization of periodontal health) should be performed prior to initiating therapy. (See <a class="local">'Before initiation of an intravenous osteoclast inhibitor'</a> above.)</p><p></p><p class="bulletIndent3">If the patient's medical condition warrants prompt initiation of the osteoclast inhibitor (eg, rapidly progressive bone disease or acute hypercalcemia, for which the benefits of treatment outweigh the risk for MRONJ) partial or minimal evaluation protocols are suggested. Recommended dental evaluation protocols are outlined in the table  (<a class="graphic graphic_table graphicRef121989" href="/z/d/graphic/121989.html" rel="external">table 5</a>).</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>During therapy, all patients should practice good oral hygiene, including daily brushing, flossing, and use of antibacterial oral rinses, and attending recommended dental check-ups, denture fittings, and routine cleanings  (<a class="graphic graphic_table graphicRef121987" href="/z/d/graphic/121987.html" rel="external">table 4</a>). Patients should inform their dentists they are receiving an osteoclast inhibitor and/or antiangiogenic agents so invasive dental procedures, especially extractions, can be avoided. (See <a class="local">'Asymptomatic patients during therapy'</a> above.)</p><p></p><p class="bulletIndent3">If an invasive dental procedure is unavoidable during osteoclast inhibitor therapy, evidence is lacking regarding the benefit of discontinuing at-risk therapies for a short period of time (ie, "drug holiday"). However, we suggest withholding the osteoclast inhibitor for two to three months before and after the invasive procedure (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>), with resumption after the mucosa has healed, if doing so is consistent with the oncologic goals of care. (See <a class="local">'Cessation of at-risk medication prior to invasive dental procedures'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For patients who develop MRONJ while receiving therapy with an osteoclast inhibitor, recommendations on management are hindered by a lack of robust evidence. Treatment objectives are to eliminate pain, control infection of the soft tissue and bone, and minimize the progression or occurrence of bone necrosis (see <a class="local">'Treatment of established MRONJ'</a> above):</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>For most patients, we suggest initial conservative management (antimicrobial mouth rinses, antibiotics [if clinically indicated  (<a class="graphic graphic_table graphicRef96868" href="/z/d/graphic/96868.html" rel="external">table 1</a>)], effective oral hygiene, and limited debridement) rather than aggressive surgical resection (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>). A short course of <a class="drug drug_general" data-topicid="10178" href="/z/d/drug information/10178.html" rel="external">teriparatide</a> (ie, eight weeks) can be offered to patients who have prolonged, nonhealing MRONJ prior to pursuing aggressive surgical options. The decision to use the drug must balance the likelihood of short-term benefit against potential (although likely remote) safety concerns. (See <a class="local">'Teriparatide'</a> above.)</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>We reserve aggressive surgical interventions (eg, mucosal flap elevation, block resection of necrotic bone, or soft tissue closure) should be reserved for refractory or advanced cases.</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Limited data suggest potential benefit for a variety of other nonsurgical treatment strategies, including parathyroid hormone (<a class="drug drug_general" data-topicid="10178" href="/z/d/drug information/10178.html" rel="external">teriparatide</a>), <a class="drug drug_general" data-topicid="9757" href="/z/d/drug information/9757.html" rel="external">pentoxifylline</a> and <a class="drug drug_general" data-topicid="10049" href="/z/d/drug information/10049.html" rel="external">vitamin E</a>, low-level laser irradiation, hyperbaric oxygen, and topical application of medical ozone, although none can yet be considered a standard approach. (See <a class="local">'Nonsurgical treatment strategies'</a> above.)</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>There are no prospective data to advise the patient or clinician as to the benefits of discontinuing therapy with an osteoclast inhibitor or antiangiogenic agent, and there is no consensus on this point. While discontinuation of the offending agent might stabilize sites of MRONJ, reduce the risk of developing new sites, and control symptoms, treatment discontinuation could also result in a recurrence of bone pain or an increase in skeletal-related events for patients receiving osteoclast inhibitor therapy in the setting of bone metastases, and a worsening of disease status in patients receiving antiangiogenic agents. (See <a class="local">'Should the at-risk agent be discontinued?'</a> above.)</p><p></p><p class="bulletIndent3">Although many oncologists, including several authors and editors associated with this topic review, discontinue the offending agent until the MRONJ is healed, there is no consensus on this point. The decision about whether to interrupt therapy must be individualized and made in concert with the dental and oncologic team and patient. Because of the rarity of this complication, there is unlikely to be a prospective clinical trial to answer this question. The decision must be made on a case-by-case basis, taking into account the estimated risks and benefits for the individual patient.</p><p></p><p class="headingAnchor" id="H742609826"><span class="h1">ACKNOWLEDGMENT</span><span class="headingEndMark"> — </span>The UpToDate editorial staff acknowledges Robert A Kyle, MD, who contributed to an earlier version of this topic review.</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Edwards BJ, Gounder M, McKoy JM, et al. Pharmacovigilance and reporting oversight in US FDA fast-track process: bisphosphonates and osteonecrosis of the jaw. Lancet Oncol 2008; 9:1166.</a></li><li><a class="nounderline abstract_t">Khosla S, Burr D, Cauley J, et al. Bisphosphonate-associated osteonecrosis of the jaw: report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res 2007; 22:1479.</a></li><li><a class="nounderline abstract_t">Hoff AO, Toth BB, Altundag K, et al. Frequency and risk factors associated with osteonecrosis of the jaw in cancer patients treated with intravenous bisphosphonates. J Bone Miner Res 2008; 23:826.</a></li><li><a class="nounderline abstract_t">Zervas K, Verrou E, Teleioudis Z, et al. Incidence, risk factors and management of osteonecrosis of the jaw in patients with multiple myeloma: a single-centre experience in 303 patients. Br J Haematol 2006; 134:620.</a></li><li><a class="nounderline abstract_t">Mavrokokki T, Cheng A, Stein B, Goss A. Nature and frequency of bisphosphonate-associated osteonecrosis of the jaws in Australia. J Oral Maxillofac Surg 2007; 65:415.</a></li><li class="breakAll">Medication-Related Osteonecrosis of the Jaw - 2014 Update. American Association of Oral and Maxillofacial Surgeons. http://www.aaoms.org/docs/position_papers/mronj_position_paper.pdf?pdf=MRONJ-Position-Paper (Accessed on September 04, 2014).</li><li><a class="nounderline abstract_t">Yarom N, Shapiro CL, Peterson DE, et al. Medication-Related Osteonecrosis of the Jaw: MASCC/ISOO/ASCO Clinical Practice Guideline. J Clin Oncol 2019; 37:2270.</a></li><li class="breakAll">Medication-Related Osteonecrosis of the Jaw – 2022 Update. American Association of Oral and Maxillofacial Surgeons. Available at: https://www.aaoms.org/docs/govt_affairs/advocacy_white_papers/mronj_position_paper.pdf (Accessed on January 03, 2023).</li><li><a class="nounderline abstract_t">Khan AA, Morrison A, Hanley DA, et al. Diagnosis and management of osteonecrosis of the jaw: a systematic review and international consensus. J Bone Miner Res 2015; 30:3.</a></li><li><a class="nounderline abstract_t">Allen MR, Burr DB. The pathogenesis of bisphosphonate-related osteonecrosis of the jaw: so many hypotheses, so few data. J Oral Maxillofac Surg 2009; 67:61.</a></li><li><a class="nounderline abstract_t">Katsarelis H, Shah NP, Dhariwal DK, Pazianas M. Infection and medication-related osteonecrosis of the jaw. J Dent Res 2015; 94:534.</a></li><li><a class="nounderline abstract_t">Allen MR, Kubek DJ, Burr DB. Cancer treatment dosing regimens of zoledronic acid result in near-complete suppression of mandible intracortical bone remodeling in beagle dogs. J Bone Miner Res 2010; 25:98.</a></li><li><a class="nounderline abstract_t">Ristow O, Gerngroß C, Schwaiger M, et al. Is bone turnover of jawbone and its possible over suppression by bisphosphonates of etiologic importance in pathogenesis of bisphosphonate-related osteonecrosis? J Oral Maxillofac Surg 2014; 72:903.</a></li><li><a class="nounderline abstract_t">Zandi M, Dehghan A, Janbaz P, et al. The starting point for bisphosphonate-related osteonecrosis of the jaw: Alveolar bone or oral mucosa? A randomized, controlled experimental study. J Craniomaxillofac Surg 2017; 45:157.</a></li><li><a class="nounderline abstract_t">Wood J, Bonjean K, Ruetz S, et al. Novel antiangiogenic effects of the bisphosphonate compound zoledronic acid. J Pharmacol Exp Ther 2002; 302:1055.</a></li><li><a class="nounderline abstract_t">Santini D, Vincenzi B, Dicuonzo G, et al. Zoledronic acid induces significant and long-lasting modifications of circulating angiogenic factors in cancer patients. Clin Cancer Res 2003; 9:2893.</a></li><li><a class="nounderline abstract_t">Hansen T, Kunkel M, Weber A, James Kirkpatrick C. Osteonecrosis of the jaws in patients treated with bisphosphonates - histomorphologic analysis in comparison with infected osteoradionecrosis. J Oral Pathol Med 2006; 35:155.</a></li><li><a class="nounderline abstract_t">Allen MR, Burr DB. Mandible matrix necrosis in beagle dogs after 3 years of daily oral bisphosphonate treatment. J Oral Maxillofac Surg 2008; 66:987.</a></li><li><a class="nounderline abstract_t">Hoefert S, Schmitz I, Tannapfel A, Eufinger H. Importance of microcracks in etiology of bisphosphonate-related osteonecrosis of the jaw: a possible pathogenetic model of symptomatic and non-symptomatic osteonecrosis of the jaw based on scanning electron microscopy findings. Clin Oral Investig 2010; 14:271.</a></li><li><a class="nounderline abstract_t">Pazianas M. Osteonecrosis of the jaw and the role of macrophages. J Natl Cancer Inst 2011; 103:232.</a></li><li><a class="nounderline abstract_t">Kos M, Junka A, Smutnicka D, et al. Pamidronate enhances bacterial adhesion to bone hydroxyapatite. Another puzzle in the pathology of bisphosphonate-related osteonecrosis of the jaw? J Oral Maxillofac Surg 2013; 71:1010.</a></li><li><a class="nounderline abstract_t">Sedghizadeh PP, Kumar SK, Gorur A, et al. Microbial biofilms in osteomyelitis of the jaw and osteonecrosis of the jaw secondary to bisphosphonate therapy. J Am Dent Assoc 2009; 140:1259.</a></li><li><a class="nounderline abstract_t">Wanger G, Gorby Y, El-Naggar MY, et al. Electrically conductive bacterial nanowires in bisphosphonate-related osteonecrosis of the jaw biofilms. Oral Surg Oral Med Oral Pathol Oral Radiol 2013; 115:71.</a></li><li><a class="nounderline abstract_t">Estilo CL, Van Poznak CH, Wiliams T, et al. Osteonecrosis of the maxilla and mandible in patients with advanced cancer treated with bisphosphonate therapy. Oncologist 2008; 13:911.</a></li><li><a class="nounderline abstract_t">Saussez S, Javadian R, Hupin C, et al. Bisphosphonate-related osteonecrosis of the jaw and its associated risk factors: a Belgian case series. Laryngoscope 2009; 119:323.</a></li><li><a class="nounderline abstract_t">Naik NH, Russo TA. Bisphosphonate-related osteonecrosis of the jaw: the role of actinomyces. Clin Infect Dis 2009; 49:1729.</a></li><li><a class="nounderline abstract_t">Sedghizadeh PP, Kumar SK, Gorur A, et al. Identification of microbial biofilms in osteonecrosis of the jaws secondary to bisphosphonate therapy. J Oral Maxillofac Surg 2008; 66:767.</a></li><li><a class="nounderline abstract_t">Reid IR, Bolland MJ, Grey AB. Is bisphosphonate-associated osteonecrosis of the jaw caused by soft tissue toxicity? Bone 2007; 41:318.</a></li><li><a class="nounderline abstract_t">Scheper MA, Badros A, Chaisuparat R, et al. Effect of zoledronic acid on oral fibroblasts and epithelial cells: a potential mechanism of bisphosphonate-associated osteonecrosis. Br J Haematol 2009; 144:667.</a></li><li><a class="nounderline abstract_t">Geissmann F, Manz MG, Jung S, et al. Development of monocytes, macrophages, and dendritic cells. Science 2010; 327:656.</a></li><li><a class="nounderline abstract_t">Roelofs AJ, Coxon FP, Ebetino FH, et al. Fluorescent risedronate analogues reveal bisphosphonate uptake by bone marrow monocytes and localization around osteocytes in vivo. J Bone Miner Res 2010; 25:606.</a></li><li><a class="nounderline abstract_t">Badros A, Weikel D, Salama A, et al. Osteonecrosis of the jaw in multiple myeloma patients: clinical features and risk factors. J Clin Oncol 2006; 24:945.</a></li><li><a class="nounderline abstract_t">Drake MT, Clarke BL, Khosla S. Bisphosphonates: mechanism of action and role in clinical practice. Mayo Clin Proc 2008; 83:1032.</a></li><li><a class="nounderline abstract_t">Bertoldo F, Santini D, Lo Cascio V. Bisphosphonates and osteomyelitis of the jaw: a pathogenic puzzle. Nat Clin Pract Oncol 2007; 4:711.</a></li><li><a class="nounderline abstract_t">Raje N, Woo SB, Hande K, et al. Clinical, radiographic, and biochemical characterization of multiple myeloma patients with osteonecrosis of the jaw. Clin Cancer Res 2008; 14:2387.</a></li><li><a class="nounderline abstract_t">Van den Wyngaert T, Huizing MT, Fossion E, Vermorken JB. Bisphosphonates in oncology: rising stars or fallen heroes. Oncologist 2009; 14:181.</a></li><li><a class="nounderline abstract_t">Pozzi S, Vallet S, Mukherjee S, et al. High-dose zoledronic acid impacts bone remodeling with effects on osteoblastic lineage and bone mechanical properties. Clin Cancer Res 2009; 15:5829.</a></li><li><a class="nounderline abstract_t">Allegra A, Oteri G, Nastro E, et al. Patients with bisphosphonates-associated osteonecrosis of the jaw have reduced circulating endothelial cells. Hematol Oncol 2007; 25:164.</a></li><li><a class="nounderline abstract_t">Allen MR, Ruggiero SL. A review of pharmaceutical agents and oral bone health: how osteonecrosis of the jaw has affected the field. Int J Oral Maxillofac Implants 2014; 29:e45.</a></li><li><a class="nounderline abstract_t">Fedele S, Porter SR, D'Aiuto F, et al. Nonexposed variant of bisphosphonate-associated osteonecrosis of the jaw: a case series. Am J Med 2010; 123:1060.</a></li><li><a class="nounderline abstract_t">Woo SB, Hellstein JW, Kalmar JR. Narrative [corrected] review: bisphosphonates and osteonecrosis of the jaws. Ann Intern Med 2006; 144:753.</a></li><li><a class="nounderline abstract_t">Saad F, Brown JE, Van Poznak C, et al. Incidence, risk factors, and outcomes of osteonecrosis of the jaw: integrated analysis from three blinded active-controlled phase III trials in cancer patients with bone metastases. Ann Oncol 2012; 23:1341.</a></li><li><a class="nounderline abstract_t">Phal PM, Myall RW, Assael LA, Weissman JL. Imaging findings of bisphosphonate-associated osteonecrosis of the jaws. AJNR Am J Neuroradiol 2007; 28:1139.</a></li><li><a class="nounderline abstract_t">Treister NS, Friedland B, Woo SB. Use of cone-beam computerized tomography for evaluation of bisphosphonate-associated osteonecrosis of the jaws. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2010; 109:753.</a></li><li><a class="nounderline abstract_t">Arce K, Assael LA, Weissman JL, Markiewicz MR. Imaging findings in bisphosphonate-related osteonecrosis of jaws. J Oral Maxillofac Surg 2009; 67:75.</a></li><li><a class="nounderline abstract_t">Vescovi P, Nammour S. Bisphosphonate-Related Osteonecrosis of the Jaw (BRONJ) therapy. A critical review. Minerva Stomatol 2010; 59:181.</a></li><li><a class="nounderline abstract_t">Chiandussi S, Biasotto M, Dore F, et al. Clinical and diagnostic imaging of bisphosphonate-associated osteonecrosis of the jaws. Dentomaxillofac Radiol 2006; 35:236.</a></li><li><a class="nounderline abstract_t">O'Ryan FS, Khoury S, Liao W, et al. Intravenous bisphosphonate-related osteonecrosis of the jaw: bone scintigraphy as an early indicator. J Oral Maxillofac Surg 2009; 67:1363.</a></li><li><a class="nounderline abstract_t">Khan AA, Morrison A, Kendler DL, et al. Case-Based Review of Osteonecrosis of the Jaw (ONJ) and Application of the International Recommendations for Management From the International Task Force on ONJ. J Clin Densitom 2017; 20:8.</a></li><li><a class="nounderline abstract_t">Goodwin JS, Zhou J, Kuo YF, Baillargeon J. Risk of Jaw Osteonecrosis After Intravenous Bisphosphonates in Cancer Patients and Patients Without Cancer. Mayo Clin Proc 2017; 92:106.</a></li><li><a class="nounderline abstract_t">Stopeck AT, Fizazi K, Body JJ, et al. Safety of long-term denosumab therapy: results from the open label extension phase of two phase 3 studies in patients with metastatic breast and prostate cancer. Support Care Cancer 2016; 24:447.</a></li><li><a class="nounderline abstract_t">Lipton A, Saad F, Van Poznak CH, et al. Incidence of osteonecrosis of the jaw in patients receiving denosumab or zoledronic acid for bone metastases from solid tumors or multiple myeloma: Results from three phase III trials. J Clin Oncol 2013; 31S: ASCO #9640.</a></li><li><a class="nounderline abstract_t">Ruggiero SL, Dodson TB, Assael LA, et al. American Association of Oral and Maxillofacial Surgeons position paper on bisphosphonate-related osteonecrosis of the jaws--2009 update. J Oral Maxillofac Surg 2009; 67:2.</a></li><li><a class="nounderline abstract_t">Qi WX, Tang LN, He AN, et al. Risk of osteonecrosis of the jaw in cancer patients receiving denosumab: a meta-analysis of seven randomized controlled trials. Int J Clin Oncol 2014; 19:403.</a></li><li><a class="nounderline abstract_t">Mauri D, Valachis A, Polyzos IP, et al. Osteonecrosis of the jaw and use of bisphosphonates in adjuvant breast cancer treatment: a meta-analysis. Breast Cancer Res Treat 2009; 116:433.</a></li><li><a class="nounderline abstract_t">Coleman R, Woodward E, Brown J, et al. Safety of zoledronic acid and incidence of osteonecrosis of the jaw (ONJ) during adjuvant therapy in a randomised phase III trial (AZURE: BIG 01-04) for women with stage II/III breast cancer. Breast Cancer Res Treat 2011; 127:429.</a></li><li><a class="nounderline abstract_t">Palaska PK, Cartsos V, Zavras AI. Bisphosphonates and time to osteonecrosis development. Oncologist 2009; 14:1154.</a></li><li><a class="nounderline abstract_t">King AE, Umland EM. Osteonecrosis of the jaw in patients receiving intravenous or oral bisphosphonates. Pharmacotherapy 2008; 28:667.</a></li><li><a class="nounderline abstract_t">Jackson GH, Morgan GJ, Davies FE, et al. Osteonecrosis of the jaw and renal safety in patients with newly diagnosed multiple myeloma: Medical Research Council Myeloma IX Study results. Br J Haematol 2014; 166:109.</a></li><li><a class="nounderline abstract_t">Bamias A, Kastritis E, Bamia C, et al. Osteonecrosis of the jaw in cancer after treatment with bisphosphonates: incidence and risk factors. J Clin Oncol 2005; 23:8580.</a></li><li class="breakAll">Background document for meeting of advisory committee for reproductive health drugs and drug safety and risk management advisory committee. United States Food and Drug Administration. September 9, 2011. Available online at http://www.fda.gov/downloads/Advisory-Committees/CommitteesMeetingMaterials/drugs/DrugSafetyandRiskManagementAdvisoryCommittee/ucm270958.pdf (Accessed on September 11, 2014).</li><li><a class="nounderline abstract_t">Van Poznak CH, Unger JM, Darke AK, et al. Association of Osteonecrosis of the Jaw With Zoledronic Acid Treatment for Bone Metastases in Patients With Cancer. JAMA Oncol 2021; 7:246.</a></li><li><a class="nounderline abstract_t">Durie BG, Katz M, Crowley J. Osteonecrosis of the jaw and bisphosphonates. N Engl J Med 2005; 353:99.</a></li><li><a class="nounderline abstract_t">Filleul O, Crompot E, Saussez S. Bisphosphonate-induced osteonecrosis of the jaw: a review of 2,400 patient cases. J Cancer Res Clin Oncol 2010; 136:1117.</a></li><li><a class="nounderline abstract_t">Dimopoulos MA, Kastritis E, Anagnostopoulos A, et al. Osteonecrosis of the jaw in patients with multiple myeloma treated with bisphosphonates: evidence of increased risk after treatment with zoledronic acid. Haematologica 2006; 91:968.</a></li><li><a class="nounderline abstract_t">Boonyapakorn T, Schirmer I, Reichart PA, et al. Bisphosphonate-induced osteonecrosis of the jaws: prospective study of 80 patients with multiple myeloma and other malignancies. Oral Oncol 2008; 44:857.</a></li><li><a class="nounderline abstract_t">Corso A, Varettoni M, Zappasodi P, et al. A different schedule of zoledronic acid can reduce the risk of the osteonecrosis of the jaw in patients with multiple myeloma. Leukemia 2007; 21:1545.</a></li><li><a class="nounderline abstract_t">Gralow JR, Barlow WE, Paterson AHG, et al. Phase III Randomized Trial of Bisphosphonates as Adjuvant Therapy in Breast Cancer: S0307. J Natl Cancer Inst 2020; 112:698.</a></li><li><a class="nounderline abstract_t">Himelstein AL, Foster JC, Khatcheressian JL, et al. Effect of Longer-Interval vs Standard Dosing of Zoledronic Acid on Skeletal Events in Patients With Bone Metastases: A Randomized Clinical Trial. JAMA 2017; 317:48.</a></li><li><a class="nounderline abstract_t">Van Poznak C, Somerfield MR, Barlow WE, et al. Role of Bone-Modifying Agents in Metastatic Breast Cancer: An American Society of Clinical Oncology-Cancer Care Ontario Focused Guideline Update. J Clin Oncol 2017; 35:3978.</a></li><li><a class="nounderline abstract_t">Coleman R, Hadji P, Body JJ, et al. Bone health in cancer: ESMO Clinical Practice Guidelines. Ann Oncol 2020; 31:1650.</a></li><li><a class="nounderline abstract_t">Raje N, Terpos E, Willenbacher W, et al. Denosumab versus zoledronic acid in bone disease treatment of newly diagnosed multiple myeloma: an international, double-blind, double-dummy, randomised, controlled, phase 3 study. Lancet Oncol 2018; 19:370.</a></li><li><a class="nounderline abstract_t">Patel V, Mansi J, Ghosh S, et al. MRONJ risk of adjuvant bisphosphonates in early stage breast cancer. Br Dent J 2018; 224:74.</a></li><li><a class="nounderline abstract_t">Henry DH, Costa L, Goldwasser F, et al. Randomized, double-blind study of denosumab versus zoledronic acid in the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma. J Clin Oncol 2011; 29:1125.</a></li><li><a class="nounderline abstract_t">Guarneri V, Miles D, Robert N, et al. Bevacizumab and osteonecrosis of the jaw: incidence and association with bisphosphonate therapy in three large prospective trials in advanced breast cancer. Breast Cancer Res Treat 2010; 122:181.</a></li><li><a class="nounderline abstract_t">Christodoulou C, Pervena A, Klouvas G, et al. Combination of bisphosphonates and antiangiogenic factors induces osteonecrosis of the jaw more frequently than bisphosphonates alone. Oncology 2009; 76:209.</a></li><li><a class="nounderline abstract_t">Aragon-Ching JB, Dahut WL. Osteonecrosis of the jaw and the use of antiangiogenic agents: just an association? Oncologist 2008; 13:1314; author reply 1315.</a></li><li><a class="nounderline abstract_t">Brunello A, Saia G, Bedogni A, et al. Worsening of osteonecrosis of the jaw during treatment with sunitinib in a patient with metastatic renal cell carcinoma. Bone 2009; 44:173.</a></li><li><a class="nounderline abstract_t">Aragon-Ching JB, Ning YM, Chen CC, et al. Higher incidence of Osteonecrosis of the Jaw (ONJ) in patients with metastatic castration resistant prostate cancer treated with anti-angiogenic agents. Cancer Invest 2009; 27:221.</a></li><li><a class="nounderline abstract_t">Beuselinck B, Wolter P, Karadimou A, et al. Concomitant oral tyrosine kinase inhibitors and bisphosphonates in advanced renal cell carcinoma with bone metastases. Br J Cancer 2012; 107:1665.</a></li><li><a class="nounderline abstract_t">Hoefert S, Eufinger H. Sunitinib may raise the risk of bisphosphonate-related osteonecrosis of the jaw: presentation of three cases. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2010; 110:463.</a></li><li><a class="nounderline abstract_t">van Cann T, Loyson T, Verbiest A, et al. Incidence of medication-related osteonecrosis of the jaw in patients treated with both bone resorption inhibitors and vascular endothelial growth factor receptor tyrosine kinase inhibitors. Support Care Cancer 2018; 26:869.</a></li><li><a class="nounderline abstract_t">Tosi P, Zamagni E, Cangini D, et al. Osteonecrosis of the jaws in newly diagnosed multiple myeloma patients treated with zoledronic acid and thalidomide-dexamethasone. Blood 2006; 108:3951.</a></li><li><a class="nounderline abstract_t">Pozzi S, Marcheselli R, Sacchi S, et al. Bisphosphonate-associated osteonecrosis of the jaw: a review of 35 cases and an evaluation of its frequency in multiple myeloma patients. Leuk Lymphoma 2007; 48:56.</a></li><li><a class="nounderline abstract_t">Morgan GJ, Jackson GH, Davies F, et al. Efficacy and side-effect profile of long-term bisphosphonate therapy in patients (pts) with multiple myeloma (MM): MRC myeloma IX study results. J Clin Oncol 2012; 30S: ASCO #8015.</a></li><li><a class="nounderline abstract_t">Berenson JR, Yellin O, Crowley J, et al. Prognostic factors and jaw and renal complications among multiple myeloma patients treated with zoledronic acid. Am J Hematol 2011; 86:25.</a></li><li><a class="nounderline abstract_t">Jadu F, Lee L, Pharoah M, et al. A retrospective study assessing the incidence, risk factors and comorbidities of pamidronate-related necrosis of the jaws in multiple myeloma patients. Ann Oncol 2007; 18:2015.</a></li><li><a class="nounderline abstract_t">Nicolatou-Galitis O, Kouri M, Papadopoulou E, et al. Osteonecrosis of the jaw related to non-antiresorptive medications: a systematic review. Support Care Cancer 2019; 27:383.</a></li><li><a class="nounderline abstract_t">Marx RE, Sawatari Y, Fortin M, Broumand V. Bisphosphonate-induced exposed bone (osteonecrosis/osteopetrosis) of the jaws: risk factors, recognition, prevention, and treatment. J Oral Maxillofac Surg 2005; 63:1567.</a></li><li><a class="nounderline abstract_t">Kyrgidis A, Vahtsevanos K, Koloutsos G, et al. Bisphosphonate-related osteonecrosis of the jaws: a case-control study of risk factors in breast cancer patients. J Clin Oncol 2008; 26:4634.</a></li><li><a class="nounderline abstract_t">Hoff AO, Toth B, Hu M, et al. Epidemiology and risk factors for osteonecrosis of the jaw in cancer patients. Ann N Y Acad Sci 2011; 1218:47.</a></li><li><a class="nounderline abstract_t">Vahtsevanos K, Kyrgidis A, Verrou E, et al. Longitudinal cohort study of risk factors in cancer patients of bisphosphonate-related osteonecrosis of the jaw. J Clin Oncol 2009; 27:5356.</a></li><li><a class="nounderline abstract_t">Fehm T, Beck V, Banys M, et al. Bisphosphonate-induced osteonecrosis of the jaw (ONJ): Incidence and risk factors in patients with breast cancer and gynecological malignancies. Gynecol Oncol 2009; 112:605.</a></li><li><a class="nounderline abstract_t">Yamazaki T, Yamori M, Ishizaki T, et al. Increased incidence of osteonecrosis of the jaw after tooth extraction in patients treated with bisphosphonates: a cohort study. Int J Oral Maxillofac Surg 2012; 41:1397.</a></li><li><a class="nounderline abstract_t">Mozzati M, Arata V, Gallesio G. Tooth extraction in patients on zoledronic acid therapy. Oral Oncol 2012; 48:817.</a></li><li><a class="nounderline abstract_t">Scoletta M, Arata V, Arduino PG, et al. Tooth extractions in intravenous bisphosphonate-treated patients: a refined protocol. J Oral Maxillofac Surg 2013; 71:994.</a></li><li><a class="nounderline abstract_t">Tsao C, Darby I, Ebeling PR, et al. Oral health risk factors for bisphosphonate-associated jaw osteonecrosis. J Oral Maxillofac Surg 2013; 71:1360.</a></li><li><a class="nounderline abstract_t">Cetiner S, Sucak GT, Kahraman SA, et al. Osteonecrosis of the jaw in patients with multiple myeloma treated with zoledronic acid. J Bone Miner Metab 2009; 27:435.</a></li><li><a class="nounderline abstract_t">Sarasquete ME, García-Sanz R, Marín L, et al. Bisphosphonate-related osteonecrosis of the jaw is associated with polymorphisms of the cytochrome P450 CYP2C8 in multiple myeloma: a genome-wide single nucleotide polymorphism analysis. Blood 2008; 112:2709.</a></li><li><a class="nounderline abstract_t">Lehrer S, Montazem A, Ramanathan L, et al. Bisphosphonate-induced osteonecrosis of the jaws, bone markers, and a hypothesized candidate gene. J Oral Maxillofac Surg 2009; 67:159.</a></li><li><a class="nounderline abstract_t">Nicoletti P, Cartsos VM, Palaska PK, et al. Genomewide pharmacogenetics of bisphosphonate-induced osteonecrosis of the jaw: the role of RBMS3. Oncologist 2012; 17:279.</a></li><li><a class="nounderline abstract_t">Katz J, Gong Y, Salmasinia D, et al. Genetic polymorphisms and other risk factors associated with bisphosphonate induced osteonecrosis of the jaw. Int J Oral Maxillofac Surg 2011; 40:605.</a></li><li><a class="nounderline abstract_t">Marini F, Tonelli P, Cavalli L, et al. Pharmacogenetics of bisphosphonate-associated osteonecrosis of the jaw. Front Biosci (Elite Ed) 2011; 3:364.</a></li><li><a class="nounderline abstract_t">Migliorati CA, Epstein JB, Abt E, Berenson JR. Osteonecrosis of the jaw and bisphosphonates in cancer: a narrative review. Nat Rev Endocrinol 2011; 7:34.</a></li><li><a class="nounderline abstract_t">Van Poznak CH, Temin S, Yee GC, et al. American Society of Clinical Oncology executive summary of the clinical practice guideline update on the role of bone-modifying agents in metastatic breast cancer. J Clin Oncol 2011; 29:1221.</a></li><li><a class="nounderline abstract_t">Kyle RA, Yee GC, Somerfield MR, et al. American Society of Clinical Oncology 2007 clinical practice guideline update on the role of bisphosphonates in multiple myeloma. J Clin Oncol 2007; 25:2464.</a></li><li class="breakAll">European Medicines Agency. CHMP Assessment Report on Bisphosphonates and Osteonecrosis of the Jaw. London: EMA/CHMP 2011. http://www.ema.europa.eu/docs/en_GB/document_library/Other/2010/01/WC500051383.pdf (Accessed on October 16, 2014).</li><li><a class="nounderline abstract_t">Anderson K, Ismaila N, Flynn PJ, et al. Role of Bone-Modifying Agents in Multiple Myeloma: American Society of Clinical Oncology Clinical Practice Guideline Update. J Clin Oncol 2018; 36:812.</a></li><li class="breakAll">Bugueno JM, Migliorati CA. The American Academy of Oral medcine clinical practice statment: dental care for the patient on antiresorptive drug therapy. Oral Surg Oral Med Oral Pathol Oral Radiol 2019; 127:136. AVailable online at https://www.sciencedirect.com/science/article/pii/S221244031831191X?via%3Dihub (Accessed on November 23, 2021).</li><li><a class="nounderline abstract_t">Epstein JB, Güneri P, Barasch A. Appropriate and necessary oral care for people with cancer: guidance to obtain the right oral and dental care at the right time. Support Care Cancer 2014; 22:1981.</a></li><li><a class="nounderline abstract_t">Hong CHL, Hu S, Haverman T, et al. A systematic review of dental disease management in cancer patients. Support Care Cancer 2018; 26:155.</a></li><li><a class="nounderline abstract_t">Mücke T, Deppe H, Hein J, et al. Prevention of bisphosphonate-related osteonecrosis of the jaws in patients with prostate cancer treated with zoledronic acid - A prospective study over 6 years. J Craniomaxillofac Surg 2016; 44:1689.</a></li><li><a class="nounderline abstract_t">Beth-Tasdogan NH. Cochrane Database Syst Rev 2022.</a></li><li><a class="nounderline abstract_t">Ripamonti CI, Maniezzo M, Campa T, et al. Decreased occurrence of osteonecrosis of the jaw after implementation of dental preventive measures in solid tumour patients with bone metastases treated with bisphosphonates. The experience of the National Cancer Institute of Milan. Ann Oncol 2009; 20:137.</a></li><li><a class="nounderline abstract_t">Dimopoulos MA, Kastritis E, Bamia C, et al. Reduction of osteonecrosis of the jaw (ONJ) after implementation of preventive measures in patients with multiple myeloma treated with zoledronic acid. Ann Oncol 2009; 20:117.</a></li><li><a class="nounderline abstract_t">Bonacina R, Mariani U, Villa F, Villa A. Preventive strategies and clinical implications for bisphosphonate-related osteonecrosis of the jaw: a review of 282 patients. J Can Dent Assoc 2011; 77:b147.</a></li><li><a class="nounderline abstract_t">Vandone AM, Donadio M, Mozzati M, et al. Impact of dental care in the prevention of bisphosphonate-associated osteonecrosis of the jaw: a single-center clinical experience. Ann Oncol 2012; 23:193.</a></li><li><a class="nounderline abstract_t">Owosho AA, Liang STY, Sax AZ, et al. Medication-related osteonecrosis of the jaw: An update on the memorial sloan kettering cancer center experience and the role of premedication dental evaluation in prevention. Oral Surg Oral Med Oral Pathol Oral Radiol 2018; 125:440.</a></li><li><a class="nounderline abstract_t">Sim IeW, Sanders KM, Borromeo GL, et al. Declining Incidence of Medication-Related Osteonecrosis of the Jaw in Patients With Cancer. J Clin Endocrinol Metab 2015; 100:3887.</a></li><li><a class="nounderline abstract_t">Bagan JV, Jiménez Y, Gómez D, et al. Collagen telopeptide (serum CTX) and its relationship with the size and number of lesions in osteonecrosis of the jaws in cancer patients on intravenous bisphosphonates. Oral Oncol 2008; 44:1088.</a></li><li><a class="nounderline abstract_t">Kunchur R, Need A, Hughes T, Goss A. Clinical investigation of C-terminal cross-linking telopeptide test in prevention and management of bisphosphonate-associated osteonecrosis of the jaws. J Oral Maxillofac Surg 2009; 67:1167.</a></li><li><a class="nounderline abstract_t">Lehrer S, Montazem A, Ramanathan L, et al. Normal serum bone markers in bisphosphonate-induced osteonecrosis of the jaws. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2008; 106:389.</a></li><li><a class="nounderline abstract_t">Montefusco V, Gay F, Spina F, et al. Antibiotic prophylaxis before dental procedures may reduce the incidence of osteonecrosis of the jaw in patients with multiple myeloma treated with bisphosphonates. Leuk Lymphoma 2008; 49:2156.</a></li><li><a class="nounderline abstract_t">Lazarovici TS, Yahalom R, Taicher S, et al. Bisphosphonate-related osteonecrosis of the jaws: a single-center study of 101 patients. J Oral Maxillofac Surg 2009; 67:850.</a></li><li><a class="nounderline abstract_t">Bilezikian JP. Osteonecrosis of the jaw--do bisphosphonates pose a risk? N Engl J Med 2006; 355:2278.</a></li><li><a class="nounderline abstract_t">Kademani D, Koka S, Lacy MQ, Rajkumar SV. Primary surgical therapy for osteonecrosis of the jaw secondary to bisphosphonate therapy. Mayo Clin Proc 2006; 81:1100.</a></li><li><a class="nounderline abstract_t">Ruggiero SL, Mehrotra B, Rosenberg TJ, Engroff SL. Osteonecrosis of the jaws associated with the use of bisphosphonates: a review of 63 cases. J Oral Maxillofac Surg 2004; 62:527.</a></li><li><a class="nounderline abstract_t">Migliorati CA, Schubert MM, Peterson DE, Seneda LM. Bisphosphonate-associated osteonecrosis of mandibular and maxillary bone: an emerging oral complication of supportive cancer therapy. Cancer 2005; 104:83.</a></li><li><a class="nounderline abstract_t">Farrugia MC, Summerlin DJ, Krowiak E, et al. Osteonecrosis of the mandible or maxilla associated with the use of new generation bisphosphonates. Laryngoscope 2006; 116:115.</a></li><li><a class="nounderline abstract_t">Tirelli G, Biasotto M, Chiandussi S, et al. Bisphosphonate-associated osteonecrosis of the jaws: the limits of a conservative approach. Head Neck 2009; 31:1249.</a></li><li><a class="nounderline abstract_t">Seth R, Futran ND, Alam DS, Knott PD. Outcomes of vascularized bone graft reconstruction of the mandible in bisphosphonate-related osteonecrosis of the jaws. Laryngoscope 2010; 120:2165.</a></li><li><a class="nounderline abstract_t">Ferlito S, Puzzo S, Palermo F, Verzì P. Treatment of bisphosphonate-related osteonecrosis of the jaws: presentation of a protocol and an observational longitudinal study of an Italian series of cases. Br J Oral Maxillofac Surg 2012; 50:425.</a></li><li><a class="nounderline abstract_t">Scoletta M, Arduino PG, Dalmasso P, et al. Treatment outcomes in patients with bisphosphonate-related osteonecrosis of the jaws: a prospective study. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2010; 110:46.</a></li><li><a class="nounderline abstract_t">Lacy MQ, Dispenzieri A, Gertz MA, et al. Mayo clinic consensus statement for the use of bisphosphonates in multiple myeloma. Mayo Clin Proc 2006; 81:1047.</a></li><li><a class="nounderline abstract_t">Wutzl A, Pohl S, Sulzbacher I, et al. Factors influencing surgical treatment of bisphosphonate-related osteonecrosis of the jaws. Head Neck 2012; 34:194.</a></li><li><a class="nounderline abstract_t">Hinson AM, Siegel ER, Stack BC Jr. Temporal correlation between bisphosphonate termination and symptom resolution in osteonecrosis of the jaw: a pooled case report analysis. J Oral Maxillofac Surg 2015; 73:53.</a></li><li><a class="nounderline abstract_t">Montebugnoli L, Felicetti L, Gissi DB, et al. Biphosphonate-associated osteonecrosis can be controlled by nonsurgical management. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2007; 104:473.</a></li><li><a class="nounderline abstract_t">Marx RE, Cillo JE Jr, Ulloa JJ. Oral bisphosphonate-induced osteonecrosis: risk factors, prediction of risk using serum CTX testing, prevention, and treatment. J Oral Maxillofac Surg 2007; 65:2397.</a></li><li><a class="nounderline abstract_t">Terpos E, Sezer O, Croucher PI, et al. The use of bisphosphonates in multiple myeloma: recommendations of an expert panel on behalf of the European Myeloma Network. Ann Oncol 2009; 20:1303.</a></li><li><a class="nounderline abstract_t">Khan AA, Sándor GK, Dore E, et al. Canadian consensus practice guidelines for bisphosphonate associated osteonecrosis of the jaw. J Rheumatol 2008; 35:1391.</a></li><li class="breakAll">Medication-Related Osteonecrosis of the Jaw – 2022 Update. American Association of Oral and Maxillofacial Surgeons. Available at: https://www.aaoms.org/docs/govt_affairs/advocacy_white_papers/mronj_position_paper.pdf (Accessed on January 24, 2023).</li><li class="breakAll">DailyMed Index. Available at: http://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?id=50538 (Accessed on November 22, 2011).</li><li class="breakAll">DailyMed Index. Available at: http://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?id=41963 (Accessed on November 22, 2011).</li><li><a class="nounderline abstract_t">Sim IW, Borromeo GL, Tsao C, et al. Teriparatide Promotes Bone Healing in Medication-Related Osteonecrosis of the Jaw: A Placebo-Controlled, Randomized Trial. J Clin Oncol 2020; 38:2971.</a></li><li><a class="nounderline abstract_t">Morishita K, Yamada SI, Kawakita A, et al. Treatment outcomes of adjunctive teriparatide therapy for medication-related osteonecrosis of the jaw (MRONJ): A multicenter retrospective analysis in Japan. J Orthop Sci 2020; 25:1079.</a></li><li><a class="nounderline abstract_t">Cheung A, Seeman E. Teriparatide therapy for alendronate-associated osteonecrosis of the jaw. N Engl J Med 2010; 363:2473.</a></li><li><a class="nounderline abstract_t">Gomberg SJ, Wustrack RL, Napoli N, et al. Teriparatide, vitamin D, and calcium healed bilateral subtrochanteric stress fractures in a postmenopausal woman with a 13-year history of continuous alendronate therapy. J Clin Endocrinol Metab 2011; 96:1627.</a></li><li><a class="nounderline abstract_t">Black DM, Abrahamsen B, Bouxsein ML, et al. Atypical Femur Fractures: Review of Epidemiology, Relationship to Bisphosphonates, Prevention, and Clinical Management. Endocr Rev 2019; 40:333.</a></li><li><a class="nounderline abstract_t">Cipriani C, Irani D, Bilezikian JP. Safety of osteoanabolic therapy: a decade of experience. J Bone Miner Res 2012; 27:2419.</a></li><li><a class="nounderline abstract_t">Epstein MS, Wicknick FW, Epstein JB, et al. Management of bisphosphonate-associated osteonecrosis: pentoxifylline and tocopherol in addition to antimicrobial therapy. An initial case series. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2010; 110:593.</a></li><li><a class="nounderline abstract_t">Ripamonti CI, Cislaghi E, Mariani L, Maniezzo M. Efficacy and safety of medical ozone (O(3)) delivered in oil suspension applications for the treatment of osteonecrosis of the jaw in patients with bone metastases treated with bisphosphonates: Preliminary results of a phase I-II study. Oral Oncol 2011; 47:185.</a></li><li><a class="nounderline abstract_t">Agrillo A, Ungari C, Filiaci F, et al. Ozone therapy in the treatment of avascular bisphosphonate-related jaw osteonecrosis. J Craniofac Surg 2007; 18:1071.</a></li><li><a class="nounderline abstract_t">Petrucci MT, Gallucci C, Agrillo A, et al. Role of ozone therapy in the treatment of osteonecrosis of the jaws in multiple myeloma patients. Haematologica 2007; 92:1289.</a></li><li><a class="nounderline abstract_t">Freiberger JJ, Padilla-Burgos R, Chhoeu AH, et al. Hyperbaric oxygen treatment and bisphosphonate-induced osteonecrosis of the jaw: a case series. J Oral Maxillofac Surg 2007; 65:1321.</a></li><li><a class="nounderline abstract_t">Shimura K, Shimazaki C, Taniguchi K, et al. Hyperbaric oxygen in addition to antibiotic therapy is effective for bisphosphonate-induced osteonecrosis of the jaw in a patient with multiple myeloma. Int J Hematol 2006; 84:343.</a></li><li><a class="nounderline abstract_t">Erkan M, Bilgi O, Mutluoğlu M, Uzun G. Bisphosphonate-related osteonecrosis of the jaw in cancer patients and hyperbaric oxygen therapy. JOP 2009; 10:579.</a></li><li><a class="nounderline abstract_t">Freiberger JJ, Padilla-Burgos R, McGraw T, et al. What is the role of hyperbaric oxygen in the management of bisphosphonate-related osteonecrosis of the jaw: a randomized controlled trial of hyperbaric oxygen as an adjunct to surgery and antibiotics. J Oral Maxillofac Surg 2012; 70:1573.</a></li><li><a class="nounderline abstract_t">Rollason V, Laverrière A, MacDonald LC, et al. Interventions for treating bisphosphonate-related osteonecrosis of the jaw (BRONJ). Cochrane Database Syst Rev 2016; 2:CD008455.</a></li><li><a class="nounderline abstract_t">Vescovi P, Merigo E, Manfredi M, et al. Nd:YAG laser biostimulation in the treatment of bisphosphonate-associated osteonecrosis of the jaw: clinical experience in 28 cases. Photomed Laser Surg 2008; 26:37.</a></li><li><a class="nounderline abstract_t">Scoletta M, Arduino PG, Reggio L, et al. Effect of low-level laser irradiation on bisphosphonate-induced osteonecrosis of the jaws: preliminary results of a prospective study. Photomed Laser Surg 2010; 28:179.</a></li><li><a class="nounderline abstract_t">Atalay B, Yalcin S, Emes Y, et al. Bisphosphonate-related osteonecrosis: laser-assisted surgical treatment or conventional surgery? Lasers Med Sci 2011; 26:815.</a></li><li><a class="nounderline abstract_t">Romeo U, Galanakis A, Marias C, et al. Observation of pain control in patients with bisphosphonate-induced osteonecrosis using low level laser therapy: preliminary results. Photomed Laser Surg 2011; 29:447.</a></li><li><a class="nounderline abstract_t">Martins MA, Martins MD, Lascala CA, et al. Association of laser phototherapy with PRP improves healing of bisphosphonate-related osteonecrosis of the jaws in cancer patients: a preliminary study. Oral Oncol 2012; 48:79.</a></li><li><a class="nounderline abstract_t">Altay MA, Tasar F, Tosun E, Kan B. Low-level laser therapy supported surgical treatment of bisphosphonate related osteonecrosis of jaws: a retrospective analysis of 11 cases. Photomed Laser Surg 2014; 32:468.</a></li><li><a class="nounderline abstract_t">Weber JB, Camilotti RS, Ponte ME. Efficacy of laser therapy in the management of bisphosphonate-related osteonecrosis of the jaw (BRONJ): a systematic review. Lasers Med Sci 2016; 31:1261.</a></li><li><a class="nounderline abstract_t">Latifyan S, Genot MT, Klastersky J. Bisphosphonate-related osteonecrosis of the jaw: a review of the potential efficacy of low-level laser therapy. Support Care Cancer 2016; 24:3687.</a></li><li><a class="nounderline abstract_t">Del Fabbro M, Gallesio G, Mozzati M. Autologous platelet concentrates for bisphosphonate-related osteonecrosis of the jaw treatment and prevention. A systematic review of the literature. Eur J Cancer 2015; 51:62.</a></li><li><a class="nounderline abstract_t">Badros A, Terpos E, Katodritou E, et al. Natural history of osteonecrosis of the jaw in patients with multiple myeloma. J Clin Oncol 2008; 26:5904.</a></li></ol></div><div id="topicVersionRevision">Topic 96863 Version 32.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19038763" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Pharmacovigilance and reporting oversight in US FDA fast-track process: bisphosphonates and osteonecrosis of the jaw.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17663640" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Bisphosphonate-associated osteonecrosis of the jaw: report of a task force of the American Society for Bone and Mineral Research.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18558816" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Frequency and risk factors associated with osteonecrosis of the jaw in cancer patients treated with intravenous bisphosphonates.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16889620" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Incidence, risk factors and management of osteonecrosis of the jaw in patients with multiple myeloma: a single-centre experience in 303 patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17307586" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Nature and frequency of bisphosphonate-associated osteonecrosis of the jaws in Australia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17307586" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Nature and frequency of bisphosphonate-associated osteonecrosis of the jaws in Australia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31329513" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Medication-Related Osteonecrosis of the Jaw: MASCC/ISOO/ASCO Clinical Practice Guideline.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31329513" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Medication-Related Osteonecrosis of the Jaw: MASCC/ISOO/ASCO Clinical Practice Guideline.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25414052" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Diagnosis and management of osteonecrosis of the jaw: a systematic review and international consensus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19371816" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : The pathogenesis of bisphosphonate-related osteonecrosis of the jaw: so many hypotheses, so few data.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25710950" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Infection and medication-related osteonecrosis of the jaw.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19580463" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Cancer treatment dosing regimens of zoledronic acid result in near-complete suppression of mandible intracortical bone remodeling in beagle dogs.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24485975" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Is bone turnover of jawbone and its possible over suppression by bisphosphonates of etiologic importance in pathogenesis of bisphosphonate-related osteonecrosis?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27919595" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : The starting point for bisphosphonate-related osteonecrosis of the jaw: Alveolar bone or oral mucosa? A randomized, controlled experimental study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12183663" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Novel antiangiogenic effects of the bisphosphonate compound zoledronic acid.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12912933" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Zoledronic acid induces significant and long-lasting modifications of circulating angiogenic factors in cancer patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16454811" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Osteonecrosis of the jaws in patients treated with bisphosphonates - histomorphologic analysis in comparison with infected osteoradionecrosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18423290" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Mandible matrix necrosis in beagle dogs after 3 years of daily oral bisphosphonate treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19536569" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Importance of microcracks in etiology of bisphosphonate-related osteonecrosis of the jaw: a possible pathogenetic model of symptomatic and non-symptomatic osteonecrosis of the jaw based on scanning electron microscopy findings.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21189409" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Osteonecrosis of the jaw and the role of macrophages.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23489958" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Pamidronate enhances bacterial adhesion to bone hydroxyapatite. Another puzzle in the pathology of bisphosphonate-related osteonecrosis of the jaw?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19797556" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Microbial biofilms in osteomyelitis of the jaw and osteonecrosis of the jaw secondary to bisphosphonate therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23217537" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Electrically conductive bacterial nanowires in bisphosphonate-related osteonecrosis of the jaw biofilms.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18695259" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Osteonecrosis of the maxilla and mandible in patients with advanced cancer treated with bisphosphonate therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19172621" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Bisphosphonate-related osteonecrosis of the jaw and its associated risk factors: a Belgian case series.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19886792" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Bisphosphonate-related osteonecrosis of the jaw: the role of actinomyces.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18355603" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Identification of microbial biofilms in osteonecrosis of the jaws secondary to bisphosphonate therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17572168" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Is bisphosphonate-associated osteonecrosis of the jaw caused by soft tissue toxicity?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19036117" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Effect of zoledronic acid on oral fibroblasts and epithelial cells: a potential mechanism of bisphosphonate-associated osteonecrosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20133564" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Development of monocytes, macrophages, and dendritic cells.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20422624" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Fluorescent risedronate analogues reveal bisphosphonate uptake by bone marrow monocytes and localization around osteocytes in vivo.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16484704" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Osteonecrosis of the jaw in multiple myeloma patients: clinical features and risk factors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18775204" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Bisphosphonates: mechanism of action and role in clinical practice.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18037875" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Bisphosphonates and osteomyelitis of the jaw: a pathogenic puzzle.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18413829" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Clinical, radiographic, and biochemical characterization of multiple myeloma patients with osteonecrosis of the jaw.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19179412" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Bisphosphonates in oncology: rising stars or fallen heroes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19737962" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : High-dose zoledronic acid impacts bone remodeling with effects on osteoblastic lineage and bone mechanical properties.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17577204" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Patients with bisphosphonates-associated osteonecrosis of the jaw have reduced circulating endothelial cells.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24451887" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : A review of pharmaceutical agents and oral bone health: how osteonecrosis of the jaw has affected the field.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20851366" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Nonexposed variant of bisphosphonate-associated osteonecrosis of the jaw: a case series.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16702591" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Narrative [corrected] review: bisphosphonates and osteonecrosis of the jaws.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21986094" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Incidence, risk factors, and outcomes of osteonecrosis of the jaw: integrated analysis from three blinded active-controlled phase III trials in cancer patients with bone metastases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17569974" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Imaging findings of bisphosphonate-associated osteonecrosis of the jaws.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20303301" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Use of cone-beam computerized tomography for evaluation of bisphosphonate-associated osteonecrosis of the jaws.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19371818" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Imaging findings in bisphosphonate-related osteonecrosis of jaws.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20360666" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Bisphosphonate-Related Osteonecrosis of the Jaw (BRONJ) therapy. A critical review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16798918" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Clinical and diagnostic imaging of bisphosphonate-associated osteonecrosis of the jaws.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19531404" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Intravenous bisphosphonate-related osteonecrosis of the jaw: bone scintigraphy as an early indicator.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27956123" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Case-Based Review of Osteonecrosis of the Jaw (ONJ) and Application of the International Recommendations for Management From the International Task Force on ONJ.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27876314" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Risk of Jaw Osteonecrosis After Intravenous Bisphosphonates in Cancer Patients and Patients Without Cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26335402" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Safety of long-term denosumab therapy: results from the open label extension phase of two phase 3 studies in patients with metastatic breast and prostate cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Incidence of osteonecrosis of the jaw in patients receiving denosumab or zoledronic acid for bone metastases from solid tumors or multiple myeloma: Results from three phase III trials</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19371809" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : American Association of Oral and Maxillofacial Surgeons position paper on bisphosphonate-related osteonecrosis of the jaws--2009 update.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23605142" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Risk of osteonecrosis of the jaw in cancer patients receiving denosumab: a meta-analysis of seven randomized controlled trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19521766" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Osteonecrosis of the jaw and use of bisphosphonates in adjuvant breast cancer treatment: a meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21394500" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Safety of zoledronic acid and incidence of osteonecrosis of the jaw (ONJ) during adjuvant therapy in a randomised phase III trial (AZURE: BIG 01-04) for women with stage II/III breast cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19897878" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Bisphosphonates and time to osteonecrosis development.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18447663" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Osteonecrosis of the jaw in patients receiving intravenous or oral bisphosphonates.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24673708" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Osteonecrosis of the jaw and renal safety in patients with newly diagnosed multiple myeloma: Medical Research Council Myeloma IX Study results.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16314620" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Osteonecrosis of the jaw in cancer after treatment with bisphosphonates: incidence and risk factors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16314620" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Osteonecrosis of the jaw in cancer after treatment with bisphosphonates: incidence and risk factors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33331905" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Association of Osteonecrosis of the Jaw With Zoledronic Acid Treatment for Bone Metastases in Patients With Cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16000365" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Osteonecrosis of the jaw and bisphosphonates.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20508948" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Bisphosphonate-induced osteonecrosis of the jaw: a review of 2,400 patient cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16757414" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Osteonecrosis of the jaw in patients with multiple myeloma treated with bisphosphonates: evidence of increased risk after treatment with zoledronic acid.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18282788" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Bisphosphonate-induced osteonecrosis of the jaws: prospective study of 80 patients with multiple myeloma and other malignancies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17410188" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : A different schedule of zoledronic acid can reduce the risk of the osteonecrosis of the jaw in patients with multiple myeloma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31693129" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Phase III Randomized Trial of Bisphosphonates as Adjuvant Therapy in Breast Cancer: S0307.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28030702" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Effect of Longer-Interval vs Standard Dosing of Zoledronic Acid on Skeletal Events in Patients With Bone Metastases: A Randomized Clinical Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29035643" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Role of Bone-Modifying Agents in Metastatic Breast Cancer: An American Society of Clinical Oncology-Cancer Care Ontario Focused Guideline Update.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32801018" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Bone health in cancer: ESMO Clinical Practice Guidelines.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29429912" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Denosumab versus zoledronic acid in bone disease treatment of newly diagnosed multiple myeloma: an international, double-blind, double-dummy, randomised, controlled, phase 3 study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29242516" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : MRONJ risk of adjuvant bisphosphonates in early stage breast cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21343556" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : Randomized, double-blind study of denosumab versus zoledronic acid in the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20361252" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : Bevacizumab and osteonecrosis of the jaw: incidence and association with bisphosphonate therapy in three large prospective trials in advanced breast cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19212145" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : Combination of bisphosphonates and antiangiogenic factors induces osteonecrosis of the jaw more frequently than bisphosphonates alone.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19088325" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : Osteonecrosis of the jaw and the use of antiangiogenic agents: just an association?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18849018" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : Worsening of osteonecrosis of the jaw during treatment with sunitinib in a patient with metastatic renal cell carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19235596" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : Higher incidence of Osteonecrosis of the Jaw (ONJ) in patients with metastatic castration resistant prostate cancer treated with anti-angiogenic agents.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23132391" id="rid79" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>80 : Concomitant oral tyrosine kinase inhibitors and bisphosphonates in advanced renal cell carcinoma with bone metastases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20692189" id="rid80" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>81 : Sunitinib may raise the risk of bisphosphonate-related osteonecrosis of the jaw: presentation of three cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28963584" id="rid81" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>82 : Incidence of medication-related osteonecrosis of the jaw in patients treated with both bone resorption inhibitors and vascular endothelial growth factor receptor tyrosine kinase inhibitors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17114572" id="rid82" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>83 : Osteonecrosis of the jaws in newly diagnosed multiple myeloma patients treated with zoledronic acid and thalidomide-dexamethasone.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17325848" id="rid83" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>84 : Bisphosphonate-associated osteonecrosis of the jaw: a review of 35 cases and an evaluation of its frequency in multiple myeloma patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid84" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>85 : Efficacy and side-effect profile of long-term bisphosphonate therapy in patients (pts) with multiple myeloma (MM): MRC myeloma IX study results.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21120861" id="rid85" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>86 : Prognostic factors and jaw and renal complications among multiple myeloma patients treated with zoledronic acid.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17804475" id="rid86" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>87 : A retrospective study assessing the incidence, risk factors and comorbidities of pamidronate-related necrosis of the jaws in multiple myeloma patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30353228" id="rid87" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>88 : Osteonecrosis of the jaw related to non-antiresorptive medications: a systematic review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16243172" id="rid88" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>89 : Bisphosphonate-induced exposed bone (osteonecrosis/osteopetrosis) of the jaws: risk factors, recognition, prevention, and treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18574158" id="rid89" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>90 : Bisphosphonate-related osteonecrosis of the jaws: a case-control study of risk factors in breast cancer patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20946574" id="rid90" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>91 : Epidemiology and risk factors for osteonecrosis of the jaw in cancer patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19805682" id="rid91" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>92 : Longitudinal cohort study of risk factors in cancer patients of bisphosphonate-related osteonecrosis of the jaw.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19136147" id="rid92" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>93 : Bisphosphonate-induced osteonecrosis of the jaw (ONJ): Incidence and risk factors in patients with breast cancer and gynecological malignancies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22840716" id="rid93" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>94 : Increased incidence of osteonecrosis of the jaw after tooth extraction in patients treated with bisphosphonates: a cohort study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22483860" id="rid94" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>95 : Tooth extraction in patients on zoledronic acid therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23434159" id="rid95" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>96 : Tooth extractions in intravenous bisphosphonate-treated patients: a refined protocol.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23582590" id="rid96" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>97 : Oral health risk factors for bisphosphonate-associated jaw osteonecrosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19240969" id="rid97" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>98 : Osteonecrosis of the jaw in patients with multiple myeloma treated with zoledronic acid.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18594024" id="rid98" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>99 : Bisphosphonate-related osteonecrosis of the jaw is associated with polymorphisms of the cytochrome P450 CYP2C8 in multiple myeloma: a genome-wide single nucleotide polymorphism analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19070762" id="rid99" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>100 : Bisphosphonate-induced osteonecrosis of the jaws, bone markers, and a hypothesized candidate gene.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22267851" id="rid100" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>101 : Genomewide pharmacogenetics of bisphosphonate-induced osteonecrosis of the jaw: the role of RBMS3.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21396799" id="rid101" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>102 : Genetic polymorphisms and other risk factors associated with bisphosphonate induced osteonecrosis of the jaw.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21196316" id="rid102" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>103 : Pharmacogenetics of bisphosphonate-associated osteonecrosis of the jaw.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21079615" id="rid103" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>104 : Osteonecrosis of the jaw and bisphosphonates in cancer: a narrative review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21343561" id="rid104" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>105 : American Society of Clinical Oncology executive summary of the clinical practice guideline update on the role of bone-modifying agents in metastatic breast cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17515569" id="rid105" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>106 : American Society of Clinical Oncology 2007 clinical practice guideline update on the role of bisphosphonates in multiple myeloma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17515569" id="rid106" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>107 : American Society of Clinical Oncology 2007 clinical practice guideline update on the role of bisphosphonates in multiple myeloma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29341831" id="rid107" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>108 : Role of Bone-Modifying Agents in Multiple Myeloma: American Society of Clinical Oncology Clinical Practice Guideline Update.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29341831" id="rid108" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>109 : Role of Bone-Modifying Agents in Multiple Myeloma: American Society of Clinical Oncology Clinical Practice Guideline Update.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24676676" id="rid109" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>110 : Appropriate and necessary oral care for people with cancer: guidance to obtain the right oral and dental care at the right time.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28735355" id="rid110" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>111 : A systematic review of dental disease management in cancer patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27555374" id="rid111" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>112 : Prevention of bisphosphonate-related osteonecrosis of the jaws in patients with prostate cancer treated with zoledronic acid - A prospective study over 6 years.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid112" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>113 : </p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18647964" id="rid113" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>114 : Decreased occurrence of osteonecrosis of the jaw after implementation of dental preventive measures in solid tumour patients with bone metastases treated with bisphosphonates. The experience of the National Cancer Institute of Milan.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18689864" id="rid114" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>115 : Reduction of osteonecrosis of the jaw (ONJ) after implementation of preventive measures in patients with multiple myeloma treated with zoledronic acid.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22129778" id="rid115" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>116 : Preventive strategies and clinical implications for bisphosphonate-related osteonecrosis of the jaw: a review of 282 patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21427065" id="rid116" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>117 : Impact of dental care in the prevention of bisphosphonate-associated osteonecrosis of the jaw: a single-center clinical experience.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29580668" id="rid117" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>118 : Medication-related osteonecrosis of the jaw: An update on the memorial sloan kettering cancer center experience and the role of premedication dental evaluation in prevention.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26241323" id="rid118" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>119 : Declining Incidence of Medication-Related Osteonecrosis of the Jaw in Patients With Cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18396443" id="rid119" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>120 : Collagen telopeptide (serum CTX) and its relationship with the size and number of lesions in osteonecrosis of the jaws in cancer patients on intravenous bisphosphonates.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19446200" id="rid120" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>121 : Clinical investigation of C-terminal cross-linking telopeptide test in prevention and management of bisphosphonate-associated osteonecrosis of the jaws.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18554944" id="rid121" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>122 : Normal serum bone markers in bisphosphonate-induced osteonecrosis of the jaws.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19021059" id="rid122" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>123 : Antibiotic prophylaxis before dental procedures may reduce the incidence of osteonecrosis of the jaw in patients with multiple myeloma treated with bisphosphonates.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19304045" id="rid123" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>124 : Bisphosphonate-related osteonecrosis of the jaws: a single-center study of 101 patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17135582" id="rid124" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>125 : Osteonecrosis of the jaw--do bisphosphonates pose a risk?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16901034" id="rid125" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>126 : Primary surgical therapy for osteonecrosis of the jaw secondary to bisphosphonate therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15122554" id="rid126" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>127 : Osteonecrosis of the jaws associated with the use of bisphosphonates: a review of 63 cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15929121" id="rid127" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>128 : Bisphosphonate-associated osteonecrosis of mandibular and maxillary bone: an emerging oral complication of supportive cancer therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16481822" id="rid128" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>129 : Osteonecrosis of the mandible or maxilla associated with the use of new generation bisphosphonates.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19260132" id="rid129" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>130 : Bisphosphonate-associated osteonecrosis of the jaws: the limits of a conservative approach.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20824743" id="rid130" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>131 : Outcomes of vascularized bone graft reconstruction of the mandible in bisphosphonate-related osteonecrosis of the jaws.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21907470" id="rid131" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>132 : Treatment of bisphosphonate-related osteonecrosis of the jaws: presentation of a protocol and an observational longitudinal study of an Italian series of cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20452252" id="rid132" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>133 : Treatment outcomes in patients with bisphosphonate-related osteonecrosis of the jaws: a prospective study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16901028" id="rid133" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>134 : Mayo clinic consensus statement for the use of bisphosphonates in multiple myeloma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21400630" id="rid134" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>135 : Factors influencing surgical treatment of bisphosphonate-related osteonecrosis of the jaws.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25511956" id="rid135" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>136 : Temporal correlation between bisphosphonate termination and symptom resolution in osteonecrosis of the jaw: a pooled case report analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17482847" id="rid136" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>137 : Biphosphonate-associated osteonecrosis can be controlled by nonsurgical management.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18022461" id="rid137" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>138 : Oral bisphosphonate-induced osteonecrosis: risk factors, prediction of risk using serum CTX testing, prevention, and treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19465418" id="rid138" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>139 : The use of bisphosphonates in multiple myeloma: recommendations of an expert panel on behalf of the European Myeloma Network.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18528958" id="rid139" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>140 : Canadian consensus practice guidelines for bisphosphonate associated osteonecrosis of the jaw.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18528958" id="rid140" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>141 : Canadian consensus practice guidelines for bisphosphonate associated osteonecrosis of the jaw.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18528958" id="rid141" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>142 : Canadian consensus practice guidelines for bisphosphonate associated osteonecrosis of the jaw.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18528958" id="rid142" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>143 : Canadian consensus practice guidelines for bisphosphonate associated osteonecrosis of the jaw.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32614699" id="rid143" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>144 : Teriparatide Promotes Bone Healing in Medication-Related Osteonecrosis of the Jaw: A Placebo-Controlled, Randomized Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32111549" id="rid144" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>145 : Treatment outcomes of adjunctive teriparatide therapy for medication-related osteonecrosis of the jaw (MRONJ): A multicenter retrospective analysis in Japan.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20950167" id="rid145" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>146 : Teriparatide therapy for alendronate-associated osteonecrosis of the jaw.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21430030" id="rid146" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>147 : Teriparatide, vitamin D, and calcium healed bilateral subtrochanteric stress fractures in a postmenopausal woman with a 13-year history of continuous alendronate therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30169557" id="rid147" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>148 : Atypical Femur Fractures: Review of Epidemiology, Relationship to Bisphosphonates, Prevention, and Clinical Management.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23165426" id="rid148" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>149 : Safety of osteoanabolic therapy: a decade of experience.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20955948" id="rid149" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>150 : Management of bisphosphonate-associated osteonecrosis: pentoxifylline and tocopherol in addition to antimicrobial therapy. An initial case series.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21310650" id="rid150" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>151 : Efficacy and safety of medical ozone (O(3)) delivered in oil suspension applications for the treatment of osteonecrosis of the jaw in patients with bone metastases treated with bisphosphonates: Preliminary results of a phase I-II study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17912085" id="rid151" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>152 : Ozone therapy in the treatment of avascular bisphosphonate-related jaw osteonecrosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17768133" id="rid152" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>153 : Role of ozone therapy in the treatment of osteonecrosis of the jaws in multiple myeloma patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17577496" id="rid153" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>154 : Hyperbaric oxygen treatment and bisphosphonate-induced osteonecrosis of the jaw: a case series.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17118761" id="rid154" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>155 : Hyperbaric oxygen in addition to antibiotic therapy is effective for bisphosphonate-induced osteonecrosis of the jaw in a patient with multiple myeloma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19734644" id="rid155" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>156 : Bisphosphonate-related osteonecrosis of the jaw in cancer patients and hyperbaric oxygen therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22698292" id="rid156" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>157 : What is the role of hyperbaric oxygen in the management of bisphosphonate-related osteonecrosis of the jaw: a randomized controlled trial of hyperbaric oxygen as an adjunct to surgery and antibiotics.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26919630" id="rid157" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>158 : Interventions for treating bisphosphonate-related osteonecrosis of the jaw (BRONJ).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18248160" id="rid158" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>159 : Nd:YAG laser biostimulation in the treatment of bisphosphonate-associated osteonecrosis of the jaw: clinical experience in 28 cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19795990" id="rid159" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>160 : Effect of low-level laser irradiation on bisphosphonate-induced osteonecrosis of the jaws: preliminary results of a prospective study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21809068" id="rid160" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>161 : Bisphosphonate-related osteonecrosis: laser-assisted surgical treatment or conventional surgery?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21235406" id="rid161" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>162 : Observation of pain control in patients with bisphosphonate-induced osteonecrosis using low level laser therapy: preliminary results.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21940198" id="rid162" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>163 : Association of laser phototherapy with PRP improves healing of bisphosphonate-related osteonecrosis of the jaws in cancer patients: a preliminary study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25045921" id="rid163" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>164 : Low-level laser therapy supported surgical treatment of bisphosphonate related osteonecrosis of jaws: a retrospective analysis of 11 cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27025860" id="rid164" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>165 : Efficacy of laser therapy in the management of bisphosphonate-related osteonecrosis of the jaw (BRONJ): a systematic review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27029476" id="rid165" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>166 : Bisphosphonate-related osteonecrosis of the jaw: a review of the potential efficacy of low-level laser therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25466505" id="rid166" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>167 : Autologous platelet concentrates for bisphosphonate-related osteonecrosis of the jaw treatment and prevention. A systematic review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19018084" id="rid167" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>168 : Natural history of osteonecrosis of the jaw in patients with multiple myeloma.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
